Clinical trial NCT04255862
Conditions: Healthy Study Participants
Keywords: UCB4940 Bimekizumab Bioequivalence Auto-injector Healthy study participants Safety-syringe
Sponsor: UCB Biopharma SRL
Start date: 2020-02-12; Completion date: 2021-04-26
Enrollment: 71 participants; Allocation: RANDOMIZED; Intervention model: SINGLE_GROUP

Brief summary:
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector presentation, in healthy study participants.

Detailed description:

Arms: arm 1: Study participants randomized to this arm will receive bimekizumab administered subcutaneously with bimekizumab-safety syringe-2 mL presentation (test 1). arm 2: Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-safety syringe-1 mL presentation (reference 1). arm 3: Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-2 mL presentation (test 2). arm 4: Study participants randomized to this arm will receive bimekizumab administered subcutaneously with a bimekizumab-auto-injector-1 mL (reference 2).
Interventions: intervention 1: Bimekizumab
Intervention descriptions: intervention 1: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.

Protocol documents:
Prot_000.pdf: 
UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 1 of 83 
AN OPEN-LABEL, SINGLE-CENTER, RANDOMIZED, 
PARALLEL-GROUP, SINGLE-DOSE BIOEQUIVALENCE 
STUDY OF BIMEKIZUMAB GIVEN AS 1X2ML OR 2X1ML 
SUBCUTANEOUS INJECTION IN HEALTHY STUDY 
PARTICIPANTS 
PROTOCOL UP0068 AMENDMENT 1 
PHASE 1 
 
SHORT TITLE: 
A bioequivalence study of bimekizumab administered as 1x2mL or 2x1mL subcutaneously in 
healthy study participants. 
Sponsor: 
UCB Biopharma SRL 
Allée de la Recherche 60 
1070 Brussels 
BELGIUM 
Regulatory agency identifying number(s): 
Eudra CT Number: 
2019-002378-30 
NCT Number: 
NCT04255862 
Confidential Material 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 2 of 83 
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
Document History 
Document 
Date 
Type of amendment 
Amendment 1 
24 Jul 2020 
Substantial 
Original Protocol 
03 Dec 2019 
Not applicable 
 
Amendment 1 (21 Jul 2020) 
Overall Rationale for the Amendment 
UP0068 Protocol Amendment 1 was completed to adapt the risk assessment in response to the 
current coronavirus disease 2019 (COVID-19) pandemic situation and describe risk mitigation 
measures: 
Section # and Name 
Description of Change 
Brief Rationale 
Title page 
The NCT number was added. 
To update the table with 
regulatory agency 
identifying numbers 
Section 1.1 Synopsis, 
Section 1.3 Schedules of 
Activities, Section 3 
Objectives and endpoints, 
Section 5.1 Inclusion criteria; 
Section 8.2.3 Vital signs, 
Section 9.5.1 Safety analyses 
Clarification was added that 
temperature measurement will be 
tympanic. 
To mitigate risk related to 
COVID-19 
Section 1.1 Synopsis, 
Section 6.3 Measures to 
minimize bias: randomization 
and blinding, Section 9.9 
Determination of sample size 
Replacement of study participants was 
added. 
To ensure an adequate 
sample size with potential 
increased withdrawal due to 
COVID-19 
Section 1.1 Synopsis, 
Section 3 Objectives and 
endpoints 
The secondary endpoint to assess 
safety and tolerability was clarified to 
refer to treatment-emergent serious 
adverse events 
To clarify objectives and 
endpoints  
Table 1-1 Schedule of 
Activities, Section 10.2 
Clinical laboratory tests 
Testing for COVID-19 was added. 
To mitigate risk related to 
COVID-19 
Section 1.3 Schedules of 
Activities, Section 2.3.1 Risk 
assessment for coronavirus 
disease 2019, Section 5.3.4 
Other restrictions 
A pre-visit phone call to record signs 
and symptoms of COVID-19 or any 
contact with persons having confirmed 
COVID-19 was added. 
To mitigate risk related to 
COVID-19 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 3 of 83 
Section # and Name 
Description of Change 
Brief Rationale 
Section 2.3.1 Risk assessment 
for coronavirus disease 2019 
A section was added to describe the 
risks to the study related to COVID-19 
and the risk mitigation measures. 
To adapt the risk 
assessment in response to 
the current pandemic 
situation and describe risk 
mitigation measures 
Section 4.2 Scientific 
rationale for study design 
A statement was added that the study is 
appropriate for conduct during the 
COVID-19 pandemic. 
To acknowledge the risk 
assessment in response to 
the current pandemic 
situation 
Section 5.1 Inclusion criteria 
Inclusion criteria #2 and #3 were 
updated to clarify that assessments will 
be at Screening and on admission. 
To clarify time points of 
assessment 
Section 5.2 Exclusion criteria 
Three exclusion criteria related to signs 
and symptoms of COVID-19, a severe 
course of COVID-19, and positive 
testing for COVID-19 were added. 
To mitigate risk related to 
COVID-19 
Section 5.3.4 Other 
restrictions 
A section describing other lifestyle 
restrictions in the study related to 
COVID-19 was added. 
To mitigate risk related to 
COVID-19 
Section 5.4 Screen failures 
Clarification was added that 
participants may be rescreened 
following discussion with the UCB 
Study Physician. 
To mitigate risk related to 
COVID-19 
Section 6.3 Measures to 
minimize bias: randomization 
and blinding 
Clarification was added that 
pharmacokinetic concentration data 
will not be available to the study team 
until after the last scheduled procedure 
for the last participant in the study. 
To minimize bias 
Section 7.2 Study participant 
discontinuation/withdrawal 
from the study 
A withdrawal criterion related to 
confirmed COVID-19 cases was 
added. 
To mitigate risk related to 
COVID-19 
Section 8 Study assessments 
and procedures 
A sentence that procedures conducted 
as part of participant’s routine clinical 
management obtained before signing 
of the ICF may be utilized for 
screening or baseline purposes was 
removed. 
Not applicable for a study 
in healthy participants 
Section 8.3 Adverse events 
and serious adverse events 
A statement that confirmed and 
suspected cases of SARS-CoV-2 
infection will be recorded as AEs was 
added. 
To clarify that cases of 
SARS-CoV-2 infection will 
be considered AEs 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 4 of 83 
Section # and Name 
Description of Change 
Brief Rationale 
Section 8.6 Pharmacokinetics 
Pharmacokinetic samples for 
concentration measurement of 
bimekizumab may be stored for a 
maximum of 5 years (or according to 
local regulations) following the last 
study participant’s last visit at a facility 
selected by the Sponsor. 
To specify storage 
conditions for PK samples 
Section 9.1 Definition of 
analysis sets 
A new analysis set (Pharmacokinetic 
Concentration Set) was added. 
To ensure all participants 
with at least 1 reported 
plasma concentration are 
captured in the listings and 
presentations of individual 
PK concentration profiles.  
Section 9.6 Handling of 
protocol deviations 
A statement that protocol deviations 
related to COVID-19 will be listed 
separately was added. 
To clarify that protocol 
deviations related to 
COVID-19 will be reported 
Section 10.1.6 Data quality 
assurance 
A statement that monitoring visits may 
be conducted on a remote basis was 
added. 
To mitigate risk related to 
COVID-19 
Section 10.1.8 Study and site 
closure 
The study must be discontinued if the 
positive evaluation or approval is 
withdrawn by the IEC or local health 
authority. 
To specify reasons for study 
discontinuation 
Throughout  
Minor editorial and formatting 
revisions  
Minor, therefore have not 
been summarized.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 5 of 83 
SERIOUS ADVERSE EVENT REPORTING 
Serious adverse event reporting (24h) 
Fax 
Europe and Rest of the World: +32 2 386 24 21 
Email 
Global: DS_ICT@ucb.com 
SAFETY REPORTING OF ADVERSE EVENTS (SERIOUS AND 
NONSERIOUS) AND DEVICE DEFICIENCIES 
Safety reporting of adverse events (24h) 
Email 
Global: DS_ICT@ucb.com 
Fax 
+32 2 386 24 21 
Reporting of device deficiencies (24h) 
Email 
Global: qactscomplaints@ucb.com 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 6 of 83 
TABLE OF CONTENTS 
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE ...................................... 2 
SERIOUS ADVERSE EVENT REPORTING .......................................................................... 5 
1 
PROTOCOL SUMMARY ............................................................................................... 11 
1.1 Synopsis ........................................................................................................................... 11 
1.2 Schema ............................................................................................................................. 14 
1.3 Schedules of activities ...................................................................................................... 15 
2 
INTRODUCTION ........................................................................................................... 23 
2.1 Study rationale ................................................................................................................. 24 
2.2 Background ...................................................................................................................... 24 
2.3 Benefit/risk assessment .................................................................................................... 24 
2.3.1 
Risk assessment for coronavirus disease 2019 .................................................... 25 
3 
OBJECTIVES AND ENDPOINTS ................................................................................. 27 
4 
STUDY DESIGN ............................................................................................................. 28 
4.1 Overall design .................................................................................................................. 28 
4.2 Scientific rationale for study design................................................................................. 28 
4.3 Justification for dose ........................................................................................................ 28 
4.4 End of study definition ..................................................................................................... 29 
5 
STUDY POPULATION .................................................................................................. 29 
5.1 Inclusion criteria .............................................................................................................. 29 
5.2 Exclusion criteria ............................................................................................................. 30 
5.3 Lifestyle restrictions ......................................................................................................... 33 
5.3.1 
Meals and dietary restrictions .............................................................................. 33 
5.3.2 
Caffeine, alcohol, and tobacco ............................................................................. 33 
5.3.3 
Activity ................................................................................................................ 33 
5.3.4 
Other restrictions ................................................................................................. 33 
5.4 Screen failures .................................................................................................................. 33 
5.5 Rescreening ...................................................................................................................... 34 
6 
IMP/INVESTIGATIONAL DEVICE PRESENTATION (FUNCTIONAL 
SECONDARY PACKAGING) ....................................................................................... 34 
6.1 Treatments to be administered ......................................................................................... 34 
6.1.1 
Medical device presentations ............................................................................... 35 
6.1.1.1 
Bimekizumab-SS ....................................................................................... 35 
6.1.1.2 
Bimekizumab-AI ....................................................................................... 36 
6.2 Preparation, handling, storage, and accountability requirements .................................... 37 
6.2.1 
Retention samples ................................................................................................ 38 
6.3 Measures to minimize bias: randomization and blinding ................................................ 38 
6.4 Treatment compliance ...................................................................................................... 39 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 7 of 83 
6.5 Concomitant medication(s)/treatment(s).......................................................................... 39 
6.5.1 
Permitted concomitant treatments (medications and therapies) .......................... 39 
6.5.2 
Prohibited concomitant treatments (medications and therapies) ......................... 39 
6.6 Dose modification ............................................................................................................ 40 
6.7 Treatment after the end of the study ................................................................................ 40 
7 
DISCONTINUATION OF STUDY MEDICATION AND STUDY PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ........................................................................ 40 
7.1 Discontinuation of IMP .................................................................................................... 40 
7.1.1 
Criteria for study hold due to adverse events ...................................................... 40 
7.2 Study participant discontinuation/withdrawal from the study ......................................... 40 
7.3 Lost to follow up .............................................................................................................. 41 
8 
STUDY ASSESSMENTS AND PROCEDURES ........................................................... 41 
8.1 Efficacy assessments ........................................................................................................ 42 
8.2 Safety assessments ........................................................................................................... 42 
8.2.1 
Physical examination ........................................................................................... 42 
8.2.2 
Body weight and height ....................................................................................... 42 
8.2.3 
Vital signs ............................................................................................................ 42 
8.2.4 
Electrocardiograms .............................................................................................. 42 
8.2.5 
Clinical safety laboratory assessments ................................................................ 43 
8.2.6 
Tuberculosis test .................................................................................................. 43 
8.2.6.1 
Tuberculosis questionnaire ........................................................................ 43 
8.3 Adverse events and serious adverse events ..................................................................... 44 
8.3.1 
Time period and frequency for collecting AE and SAE information .................. 44 
8.3.2 
Method of detecting AEs and SAEs .................................................................... 44 
8.3.3 
Follow-up of AEs and SAEs ................................................................................ 44 
8.3.4 
Regulatory reporting requirements for SAEs ...................................................... 45 
8.3.5 
Pregnancy ............................................................................................................ 45 
8.3.6 
Adverse events of special interest ........................................................................ 45 
8.3.6.1 
Other safety topics of interest .................................................................... 46 
8.3.7 
Medical device– AEs (ADE s, UADEs, SAEs, and USADEs) and device 
presentation deficiencies ...................................................................................... 46 
8.3.7.1 
Time period for detecting medical device presentation deficiencies ........ 46 
8.3.7.2 
Follow-up of medical device presentation deficiencies ............................ 47 
8.3.7.3 
Prompt reporting of medical device presentation deficiencies to the 
Sponsor ...................................................................................................... 47 
8.3.7.4 
Regulatory reporting requirements for medical device presentation 
deficiencies ................................................................................................ 47 
8.4 Safety signal detection ..................................................................................................... 47 
8.5 Treatment of overdose ..................................................................................................... 48 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 8 of 83 
8.6 Pharmacokinetics ............................................................................................................. 48 
8.7 Genetics ............................................................................................................................ 49 
8.8 Pharmacodynamics .......................................................................................................... 49 
8.9 Biomarkers ....................................................................................................................... 49 
8.10 Immunogenicity assessments ........................................................................................... 49 
8.11 Medical resource utilization and health economics ......................................................... 49 
9 
STATISTICAL CONSIDERATIONS ............................................................................. 49 
9.1 Definition of analysis sets ................................................................................................ 49 
9.2 General statistical considerations ..................................................................................... 50 
9.3 Planned efficacy/outcome analyses ................................................................................. 50 
9.4 Planned outcome analyses ............................................................................................... 50 
9.4.1 
Analysis of the primary endpoints ....................................................................... 50 
9.4.2 
Analysis of secondary PK parameters ................................................................. 50 
9.4.3 
Study participant disposition and characteristics ................................................. 51 
9.5 Planned safety and immunogenicity analyses .................................................................. 51 
9.5.1 
Safety analyses ..................................................................................................... 51 
9.5.2 
Immunogenicity analyses .................................................................................... 51 
9.6 Handling of protocol deviations ....................................................................................... 52 
9.7 Handling of dropouts or missing data .............................................................................. 52 
9.8 Planned interim analysis and data monitoring ................................................................. 52 
9.9 Determination of sample size ........................................................................................... 52 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS... 53 
10.1 Appendix 1: Regulatory, ethical, and study oversight considerations ............................. 53 
10.1.1 
Regulatory and ethical considerations ................................................................. 53 
10.1.2 
Financial disclosure ............................................................................................. 53 
10.1.3 
Informed consent process .................................................................................... 54 
10.1.4 
Data protection ..................................................................................................... 54 
10.1.5 
Committees structure ........................................................................................... 54 
10.1.6 
Data quality assurance ......................................................................................... 55 
10.1.6.1 
Case Report form completion .................................................................... 55 
10.1.6.2 
Apps ........................................................................................................... 56 
10.1.7 
Data collection and source documents ................................................................ 56 
10.1.8 
Study and site closure .......................................................................................... 56 
10.1.9 
Publication policy ................................................................................................ 57 
10.2 Appendix 2: Clinical laboratory tests .............................................................................. 58 
10.3 Appendix 3: Adverse events – definitions and procedures for recording, evaluating, 
follow up, and reporting ................................................................................................... 60 
10.3.1 
Definition of AE .................................................................................................. 60 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 9 of 83 
10.3.2 
Definition of SAE ................................................................................................ 61 
10.3.3 
Recording and follow up of AE and/or SAE ....................................................... 62 
10.4 Appendix 4: Contraceptive guidance and collection of pregnancy information ............. 65 
10.5 Appendix 5: Genetics ....................................................................................................... 68 
10.6 Appendix 6: Liver safety – suggested actions and follow-up assessments ..................... 69 
10.7 Appendix 7: Medical device presentation AEs, ADEs, SAEs and Device Deficiencies: – 
definition and procedures for recording, evaluating, follow up, and reporting ............... 71 
10.7.1 
Definitions of a medical device presentation incident ......................................... 71 
10.7.2 
Definition of AE and ADE .................................................................................. 71 
10.7.3 
Definition of SAE, SADE and USADE .............................................................. 72 
10.7.4 
Definition of device presentation deficiency ....................................................... 72 
10.7.5 
Recording and follow up of AE and/or SAE and device deficiencies ................. 73 
10.7.6 
Reporting of SAEs ............................................................................................... 75 
10.7.7 
Reporting of SADEs ............................................................................................ 75 
10.7.8 
AE, ADE, SAE, SADE determination flow chart ............................................... 76 
10.8 Appendix 8: Rapid alert procedures ................................................................................ 77 
10.9 Appendix 9: Country-specific requirements .................................................................... 78 
10.10 
Appendix 10: Abbreviations and trademarks ........................................................ 79 
11 REFERENCES ................................................................................................................ 82 
SPONSOR DECLARATION .................................................................................................. 83 
 
LIST OF TABLES 
Table 1-1: 
Schedule of activities ....................................................................................... 16 
Table 1-2: 
Study activities from predose to 48h after IMP administration ....................... 20 
Table 1-3: 
Study activities from Day 4 to 10 after IMP administration ............................ 21 
Table 1-4: 
Study activities from Day 13 to 140 after IMP administration ........................ 22 
Table 6-1: 
Treatments to be administered ......................................................................... 34 
Table 10-1: 
Protocol-required safety laboratory assessments ............................................. 58 
Table 10-2: 
Highly effective contraceptive methods a ........................................................ 66 
Table 10-3: 
Phase I liver chemistry stopping criteria and follow-up assessments .............. 69 
 
LIST OF FIGURES 
Figure 1-1: 
Study schematic ............................................................................................... 14 
Figure 6-1: 
Bimekizumab-SS-1mL .................................................................................... 36 
Figure 6-2: 
Bimekizumab-SS-2mL .................................................................................... 36 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 10 of 83 
Figure 6-3: 
Bimekizumab-AI-1mL ..................................................................................... 37 
Figure 6-4: 
Bimekizumab-AI-2mL ..................................................................................... 37 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 11 of 83 
1 
PROTOCOL SUMMARY 
1.1 
Synopsis 
Protocol title: 
An open-label, single-center, randomized, parallel-group, single-dose bioequivalence (BE) study 
of bimekizumab given as 1x2ml or 2x1ml subcutaneous (sc) injection in healthy study 
participants. 
Short Title: 
A bioequivalence study of bimekizumab administered as 1x2mL or 2x1mL subcutaneously in 
healthy study participants. 
Rationale: 
Currently, bimekizumab 320mg (the dose being assessed in the Phase 3 psoriasis studies) is 
administered as 2x1mL sc injections of 160mg. To provide additional options to healthcare 
professionals and patients, it is considered of benefit by UCB to develop bimekizumab 320mg 
device presentations (ie, functional secondary packaging) where the dose can be delivered as a 
single 2mL sc injection. The primary objective of this study is, therefore, to compare the PK of 
bimekizumab 320mg when administered sc using a 2mL safety syringe (SS; 
bimekizumab-SS-2mL, test 1) versus 2x1mL safety syringe (bimekizumab-SS-1mL, reference 1) 
or when administered sc using a 2mL auto-injector (AI; bimekizumab-AI-2mL, test 2) versus 
2x1mL auto-injector (bimekizumab-AI-1mL, reference 2) to support the development of the 
2mL SS and AI device presentations. 
Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
To compare the PK of bimekizumab 320mg when 
administered sc using the bimekizumab-SS-2mL 
presentation (test 1) versus the bimekizumab-SS-1mL 
presentation (reference 1) or the bimekizumab-AI-2mL 
presentation (test 2) versus the bimekizumab-AI-1mL 
presentation (reference 2) in healthy study participants 
AUC, AUC(0-t), Cmax 
Secondary 
To assess 
• safety and tolerability 
• additional PK parameters 
of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL or 
bimekizumab-AI-2mL presentation in healthy study 
participants 
 
• TEAEs and treatment-emergent 
SAEs 
• t½, tmax 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 12 of 83 
Other/Exploratory 
To assess 
• additional PK parameters 
• immunogenicity 
• additional safety and tolerability 
of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL or 
bimekizumab-AI-2mL presentation in healthy study 
participants 
 
• %AUCex, CL/F, Vz/F 
• Incidence of bimekizumab 
antidrug antibodies  
• Vital signs (pulse rate, BP, and 
tympanic body temperature) 
• Safety laboratory data 
(hematology [including 
coagulation/hemostasis tests], 
clinical chemistry, and 
urinalysis) 
• 12-lead ECG assessments 
AE=adverse event; AI=auto-injector; AUC=area under the plasma concentration-time curve from time zero to 
infinity; %AUCex=percentage of the AUC extrapolated from Clast; AUC(0-t)=area under the plasma 
concentration-time curve from time zero to last observed quantifiable concentration; BP=blood pressure; 
CL/F=apparent total body clearance; Clast=last observed quantifiable plasma drug concentration; 
Cmax=maximum observed plasma drug concentration; ECG=electrocardiogram; PK=pharmacokinetic; 
SAE=serious adverse event; SS=safety syringe; TEAE=treatment-emergent adverse event; t1/2=apparent 
terminal half-life; tmax=time of occurrence of Cmax; Vz/F=apparent volume of distribution 
Overall Design 
This is a Phase 1, open-label, single-center, randomized, parallel-group, single-dose, 4 arm 
BE study to compare the pharmacokinetics (PK) of bimekizumab 320mg when administered as 
either a 1x2mL or 2x1mL sc injection in healthy male and female study participants. The SS and 
AI device presentations will be assessed. The 4 arms will be: 
bimekizumab-SS-2mL (test 1) 
bimekizumab-SS-2x1mL (reference 1) 
bimekizumab-AI-2mL (test 2) 
bimekizumab-AI-2x1mL (reference 2) 
Two independent comparisons will be made: test 1 versus reference 1 and test 2 versus 
reference 2. 
Number of Study Participants 
Assuming a dropout rate and nonevaluable study participants of approximately 10%, 100 study 
participants per group for a total of 400 study participants are to be enrolled in the study. If this 
10% rate is likely to be exceeded, due to unforeseen circumstances during the coronavirus 
disease 2019 (COVID-19) pandemic, then participants may be replaced. 
Treatment Groups and Duration 
Each study participant will receive a single-dose administration of bimekizumab 320mg 
administered sc using a 2mL SS (bimekizumab-SS-2mL, test 1) versus 2x1mL SS 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 13 of 83 
(bimekizumab-SS-1mL, reference 1) or a 2mL AI (bimekizumab-AI-2mL, test 2) versus 2x1mL 
AI (bimekizumab-AI-1mL, reference 2). The duration of the study will be approximately 
168 days, including 27 days of Screening, admission on Day -1, an inhouse Treatment Period 
from Day 1 to Day 3, Outpatient Visits until Day 112, and a Safety Follow-Up (SFU) Visit on 
Day 140. Randomization will occur on Day 1 prior to dosing. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 14 of 83 
1.2 
Schema 
The schematic diagram of this study is presented in Figure 1-1. 
Figure 1-1: Study schematic 
 
AI=auto-injector; SS=safety syringe 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 15 of 83 
1.3 
Schedules of activities 
A schedule of activities for the duration of the entire study is presented in Table 1-1. The study 
assessments conducted prior to dosing through 48 hours after investigational medicinal product 
(IMP) administration are presented in Table 1-2. The study assessments conducted from Day 4 
through Day 10 and from Day 13 through Day 140 after IMP administration are presented in 
Table 1-3 and Table 1-4, respectively. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 16 of 83 
Table 1-1: 
Schedule of activities 
Assessments 
Screening 
Inhouse Treatment Period 
Outpatient Visits 
Safety 
Follow-Up/ 
Discharge 
Day -28 to 
Day -2 
Day -1 
Day 1 
Day 1 
postdose 
to Day 3 
postdose 
Days 4 to 
10 
Days 13, 16, 
19, 22, 25, 
and 28 (±1 
day) 
Days 56, 
84, 112 
(±3 days) 
Day 140 
(±3 days) 
Admission Predose 
0 h 
Ambulatory (A)/inhouse (I) 
visit 
A 
I 
A 
A 
A 
A 
Written informed consent 
X 
 
 
 
 
 
 
 
 
Verification of 
inclusion/exclusion and 
withdrawal criteria 
X 
X 
X 
 
 
 
 
 
 
Demographic data and 
lifestyle 
X 
 
 
 
 
 
 
 
 
Medical/procedures 
history/prior medication 
X 
 
 
 
 
 
 
 
 
Urine drug and alcohol 
screen 
X 
X 
 
 
 
 
 
 
 
TB test (QuantiFERON®-TB 
GOLD PLUS) and TB 
questionnaire 
X 
 
 
 
 
 
 
 
 
Smoking habits/Fagerström 
test 
X 
 
 
 
 
 
 
 
 
Randomizationa 
 
X 
 
 
 
 
 
 
 
Pre-visit phone callb 
 
X 
 
 
 
 
X 
X 
X 
IMP administrationc 
 
 
 
X 
 
 
 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 17 of 83 
Table 1-1: 
Schedule of activities 
Assessments 
Screening 
Inhouse Treatment Period 
Outpatient Visits 
Safety 
Follow-Up/ 
Discharge 
Day -28 to 
Day -2 
Day -1 
Day 1 
Day 1 
postdose 
to Day 3 
postdose 
Days 4 to 
10 
Days 13, 16, 
19, 22, 25, 
and 28 (±1 
day) 
Days 56, 
84, 112 
(±3 days) 
Day 140 
(±3 days) 
Admission Predose 
0 h 
Physical examinationd 
X 
X 
 
 
X 
X 
X 
X 
X 
Vital signse, f 
X 
X 
X 
 
X 
Xe 
Xe 
X 
X 
Body weight and heightg 
X 
X 
 
 
 
 
 
 
X 
Single 12-lead ECGf 
X 
X 
X 
 
X 
X 
X 
X 
X 
Concomitant medication 
X 
X 
X 
 
X 
X 
X 
X 
X 
Concomitant medical 
procedures 
X 
X 
X 
 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Device presentation 
deficiencies 
 
 
 
Xh 
 
 
 
 
 
Serologyi 
X 
 
 
 
 
 
 
 
 
SARS-CoV-2 RT-PCR 
 
X 
 
 
 
 
 
 
 
Hematology (including 
coagulation/hemostasis)j 
X 
X 
 
 
X 
X 
X 
X 
X 
Clinical chemistryj 
X 
X 
 
 
X 
X 
X 
X 
X 
Urinalysis (dipstick)k 
X 
X 
 
 
X 
X 
X 
X 
X 
Blood samples for 
bimekizumab plasma 
concentrationsl 
 
 
X 
 
X 
X 
X 
X 
X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 18 of 83 
Table 1-1: 
Schedule of activities 
Assessments 
Screening 
Inhouse Treatment Period 
Outpatient Visits 
Safety 
Follow-Up/ 
Discharge 
Day -28 to 
Day -2 
Day -1 
Day 1 
Day 1 
postdose 
to Day 3 
postdose 
Days 4 to 
10 
Days 13, 16, 
19, 22, 25, 
and 28 (±1 
day) 
Days 56, 
84, 112 
(±3 days) 
Day 140 
(±3 days) 
Admission Predose 
0 h 
Blood samples for ADAbsm 
 
 
X 
 
 
 
X 
X 
X 
Pregnancy testn 
X 
X 
 
 
 
 
X 
X 
X 
Follicle-stimulating hormone 
test  
X 
 
 
 
 
 
 
 
 
A=ambulatory; Ab=antibody; ADAb=anti-drug-antibody; AE=adverse event; BP=blood pressure; COVID-19=coronavirus disease 2019; 
ECG=electrocardiogram; FSH=follicle stimulating hormone; HBsAg=hepatitis B surface antigen; HBc-Ab=hepatitis B core antibody; HCV-Ab=hepatitis C 
virus antibody; h=hour; HIV=human immunodeficiency virus; HIV1/2-Ab=HIV1/2 antibody; HIV1-Ag=HIV1 antigen; I=inhouse; IgG=immunoglobulin G; 
IgM=immunoglobulin M; IMP=investigational medicinal product; PK=pharmacokinetic(s); RT-PCR=real-time reverse transcriptase polymerase chain 
reaction; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2; sc=subcutaneous; SFU=Safety Follow-Up; TB=tuberculosis 
Note: At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the study but prior to the SFU Visit, if deemed necessary for 
the study participant’s safety and well-being. The same assessments as performed on the SFU Visit, or alternatively as advised by the Investigator, should be 
performed if a study participant is attending an Unscheduled Visit during the study. 
a Randomization will occur on the evening of Day -1, provided all information for eligibility is known. The study identification card will be given to the study 
participant following IMP administration. 
b Phone calls will be performed 1 day prior to the indicated visit to record signs and symptoms of COVID-19 or any contact with persons having confirmed 
SARS-CoV-2 infection. In case of signs/symptoms or contact, the visit will be cancelled and reason for cancellation will be appropriately documented. 
c Bimekizumab will be administered as a sc injection as detailed in Section 6. 
d A full physical examination will be performed at the Screening Visit, Day -1, and SFU Visit. On all other days (Days 2, 3, 9, 25, 56, 84, 112, and 140) a 
physical examination is planned, it will be performed symptom-driven, ie, in case of an AE. 
e Vital signs include BP, pulse rate, and tympanic body temperature. Body temperature only will be measured at outpatient visits without regular vital signs 
measurement (Days 4, 5, 6, 7, 8, 10, 13, 16, 19, 22, and 28). 
f During the inhouse treatment period, vital signs and ECGs should be measured/taken prior to blood sampling, where applicable, with the study participant 
resting in the supine position for at least 3 minutes. Vital signs and ECGs will be measured on Day 1 at predose, at 1.5h, 5h, and 11h postdose, on Day 2 at 24h 
postdose, and on Day 3 at 48 hours postdose, then on Days 9, 25, 56, 84, 112, and 140. 
g Height will be recorded only at the Screening Visit. 
h As this is a single-dose study, device presentation deficiencies are only to be captured on Day 1 (ie, the day when IMP is administered during the inhouse 
treatment period). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 19 of 83 
i Serology variables include HbsAg, HBc-Ab, HCV-Ab (both IgG and IgM), HIV1-Ab, HIV1-Ag, and HIV-2 Ab. 
j Blood sampling for hematology (including coagulation and hemostasis) and clinical chemistry will be performed at the Screening Visit, and Days -1, 2, 9, 25, 
56, 84, 112, and the SFU Visit. 
k Urinalysis via dipstick will be performed at Screening, Day-1, Days 2, 9, 25, 56, 84, 112, and 140. 
l The PK sampling time points will be as follows: predose within 15 minutes at maximum before dosing, and 1.5h, 5h, 24h, 48h postdose, and from Day 4 
onwards at every visit (ie, Days 4 to 10, 13, 16, 19, 22, 25, 28, 56, 84, 112, and 140). 
m ADAb samples will be taken predose and on Days 13, 28, 56, 84, 112, and 140; blood samples will be processed as specified in the laboratory manual. 
n Pregnancy tests will be performed at the Screening Visit, Day-1, Days 28, 56, 84, 112, and Day 140. Prior to dosing, the test should be performed in serum; 
post dosing the test may be performed in urine. The FSH test will be performed in postmenopausal women at the Screening Visit. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 20 of 83 
Table 1-2: 
Study activities from predose to 48h after IMP administration 
Assessments 
Predose 
Dosing 0h 
1.5h 
3h 
5h 
11h 
24h 
Day 2 
48h 
Day 3 
Physical examination 
 
 
 
 
 
 
X 
X 
Vital signs 
X 
 
X 
 
X 
X 
X 
X 
12-lead ECG 
X 
 
X 
 
X 
X 
X 
X 
Hematology 
 
 
 
 
 
 
X 
 
Clinical chemistry 
 
 
 
 
 
 
X 
 
Coagulation/hemostasis 
 
 
 
 
 
 
X 
 
Urinalysis (dipstick) 
 
 
 
 
 
 
X 
 
IMP administration 
 
X 
 
 
 
 
 
 
Blood samples for 
bimekizumab plasma 
concentrations 
X a 
 
X 
 
X 
 
X 
X 
Blood samples for ADAbs 
X 
 
 
 
 
 
 
 
Concomitant medication 
X 
 
X 
X 
X 
X 
X 
X 
Concomitant medical 
procedures 
X 
 
X 
X 
X 
X 
X 
X 
Adverse events/device 
presentation deficiencies 
X 
X b 
X 
X 
X 
X 
X 
X 
ADAb=antidrug antibody; ECG=electrocardiogram; h=hour; IMP=investigational medicinal product 
a  Within 15 minutes maximum before dosing. 
b  As this is a single-dose study, device presentation deficiencies are only to be captured on Day 1 (ie, the day when IMP is administered during the inhouse 
treatment period). 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 21 of 83 
Table 1-3: 
Study activities from Day 4 to 10 after IMP administration 
Assessment 
Day 4 
Day 5 
Day 6 
Day 7 
Day 8 
Day 9 
Day 10 
Physical examination 
 
 
 
 
 
X 
 
Vital signsa  
Xa 
Xa 
Xa 
Xa 
Xa 
X 
Xa 
12-lead ECG 
 
 
 
 
 
X 
 
Hematology 
 
 
 
 
 
X 
 
Clinical chemistry 
 
 
 
 
 
X 
 
Coagulation/hemostasis 
 
 
 
 
 
X 
 
Urinalysis (dipstick) 
 
 
 
 
 
X 
 
Blood samples for 
bimekizumab plasma 
concentrations 
X 
X 
X 
X 
X 
X 
X 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
Concomitant medical 
procedures 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
ECG=electrocardiogram; IMP=investigational medicinal product 
a Tympanic body temperature only will be measured at outpatient visits without regular vital signs measurement (Days 4, 5, 6, 7, 8, and 10). 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
 
24 Jul 2020 
Clinical Study Protocol 
 
Bimekizumab 
 
UP0068 
 
 
 
 
Confidential 
Page 22 of 83 
Table 1-4: 
Study activities from Day 13 to 140 after IMP administration 
Assessment 
Day 13 
Day 16 
Day 19 
Day 22 
Day 25 
Day 28 
Day 56 
Day 84 
Day 112 
Day 140 
Pre-visit phone calla 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
 
 
 
 
X 
 
X 
X 
X 
X 
Vital signsb 
Xb 
Xb 
Xb 
Xb 
X 
Xb 
X 
X 
X 
X 
Body weight 
 
 
 
 
 
 
 
 
 
X 
12-lead ECG 
 
 
 
 
X 
 
X 
X 
X 
X 
Hematology 
 
 
 
 
X 
 
X 
X 
X 
X 
Clinical chemistry 
 
 
 
 
X 
 
X 
X 
X 
X 
Coagulation/hemostasis 
 
 
 
 
X 
 
X 
X 
X 
X 
Urinalysis (dipstick) 
 
 
 
 
X 
 
X 
X 
X 
X 
Urine pregnancy test 
 
 
 
 
 
X 
X 
X 
X 
X 
Blood samples for 
bimekizumab plasma 
concentrations 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Blood samples for ADAbs 
X 
 
 
 
 
X 
X 
X 
X 
X 
Concomitant medication 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medical 
procedures 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
ADAb=antidrug antibody; COVID-19=coronavirus disease 2019; ECG=electrocardiogram; IMP=investigational medicinal product; SARS-CoV-2=severe acute 
respiratory syndrome coronavirus 2 
a Phone calls will be performed 1 day prior to the indicated visit to record signs and symptoms of COVID-19 or any contact with persons having confirmed 
SARS-CoV-2 infection. In case of signs/symptoms or contact, the visit will be cancelled and reason for cancellation will be appropriately documented. 
b Tympanic body temperature only will be measured at outpatient visits without regular vital signs measurement (Days 13, 16, 19, 22, and 28). 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 23 of 83 
2 
INTRODUCTION 
Bimekizumab is an engineered, humanized, full-length immunoglobulin (Ig) G1 monoclonal 
antibody, with high affinity for human interleukin (IL)-17A and IL-17F. Interleukin-17A has 
been shown to have a role in pathogenesis of several autoimmune disorders and anti-IL-17A 
antibodies have shown efficacy in several diseases such as psoriasis (PSO), psoriatic arthritis 
(PsA), and ankylosing spondylitis (AS) in humans, and IL-17F has been increasingly recognized 
to contribute to the pathogenesis of a number of inflammatory diseases, including PSO, PsA, 
axial spondyloarthritis (axSpA), rheumatoid arthritis (RA), and hidradenitis suppurativa (HS). 
Bimekizumab selectively and potently inhibits the activity of both IL-17A and IL-17F isoforms 
in vitro. Therefore, it permits an evaluation of the potential for additional efficacy, which may be 
conferred by dual inhibition of both cytokines, in patients suffering from diseases in which both 
cytokines are active. 
Parallel inhibition of IL-17A and IL-17F has shown potent effects in a variety of animal models 
of inflammatory disease. Intravenously administered bimekizumab was well tolerated in 
repeat-dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single-dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat-dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa-associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat-dose study, none of the minor apoptosis/necrosis findings observed in gut-associated 
lymph nodes were revealed. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa (Balantidium coli) was observed in the 
cecum and colon as compared with the control animals and low dose animals. Therefore, the 
gut-associated lymph node lesions observed in the first study are considered to be accidental 
and/or linked to exaggerated pharmacology and proliferation of Balantidium coli and are 
considered to be the result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the Investigator’s Brochure (IB). 
Twelve clinical studies of bimekizumab have been completed to date: RA0124 in 30 healthy 
study participants, UP0031 in 12 healthy study participants, UP0033 in 189 healthy study 
participants, UP0042 in 48 Japanese and Caucasian healthy male study participants, PA0007 in 
53 study participants with PsA, PA0008 in 205 study participants with PsA, RA0123 in 159 
study participants with RA, UC0011 in 23 study participants with moderate to severe ulcerative 
colitis (UC) at time of discontinuation, UP0008 in 39 study participants with mild to moderate 
plaque PSO, PS0010 in 250 study participants with moderate to severe plaque PSO, PS0011 in 
217 study participants with moderate to severe plaque PSO, and PS0016 in 48 study participants 
with moderate to severe plaque PSO. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 24 of 83 
A current list of ongoing studies and additional information on the clinical data for bimekizumab 
are available in the current version of the IB. 
2.1 
Study rationale 
Currently, bimekizumab 320mg (the dose being assessed in the Phase 3 psoriasis studies) is 
administered as 2x1mL sc injections of 160mg. To provide additional options to healthcare 
professionals and patients, it is considered of benefit (by UCB) to develop 320mg bimekizumab 
device presentations (ie, secondary functional packaging) where the dose can be delivered as a 
single 2mL sc injection. The primary objective of this study is to compare the PK of 
bimekizumab 320mg when administered sc using a 2mL safety syringe (SS; 
bimekizumab-SS-2mL, test 1) versus 2x1mL safety syringe (bimekizumab-SS-1mL, reference 1) 
or when administered sc using a 2mL auto-injector (AI; bimekizumab-AI-2mL, test 2) versus 
2x1mL auto-injector (bimekizumab-AI-1mL, reference 2) to support the development of the 
2mL SS and AI presentations. 
2.2 
Background 
UP0068 is an open-label, randomized, parallel-group, 4-arm study to explore the BE of 
bimekizumab (bimekizumab P5) administered as either 1x2mL or 2x1mL sc injections using the 
bimekizumab-SS and bimekizumab-AI in healthy study participants. 
The bioequivalence of the 2x1mL device presentations (ie, bimekizumab-SS-1mL and 
bimekizumab-AI-1mL) containing the P5 manufacturing process drug substance and the process 
and device presentation used in the Phase 3 psoriasis (PSO) studies (ie, Process 4 [P4] and the 
bimekizumab-TN [True North] prefilled syringe [PFS] presentation) is being assessed in an 
ongoing study (UP0033). UP0033 is a Phase 1, open-label, parallel-group, randomized, 3-arm, 
single-dose study of bimekizumab 320mg administered as a 2x1mL subcutaneous (sc) injection 
in healthy male and female study participants. 
2.3 
Benefit/risk assessment 
Participation in this study does not have any therapeutic benefit for the healthy study 
participants. Healthy study participants will benefit from a complete health check-up and regular 
routine blood tests throughout the course of the study. Nonetheless, the participation of healthy 
study participants in the study is of importance to the patients and the development of the 
bimekizumab-SS-2mL and the bimekizumab-AI-2mL for administration of bimekizumab. 
Currently, bimekizumab 320mg is administered as 2x1mL sc injections; therefore, UCB 
considers it a beneficial option for healthcare professionals and patients to administer 
bimekizumab 320mg as a single 1x2mL sc injection. 
Healthy study participants who participate in this study may be exposed to the: 
• Risks of the study procedures 
• Known and unknown risks related to the exposure to the IMP 
Procedure-related risks 
The use of an indwelling cannula for blood sampling may be accompanied by mild bruising and 
in rare cases, by transient inflammation of the wall of the vein. After initial irritation, the 
presence of an indwelling cannula is usually painless and hardly noticeable. The same applies to 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 25 of 83 
vein puncturing for further blood sampling. In very rare cases, a nerve might be injured while 
inserting the cannula. This could be followed by paresthesia, reduced sensitivity, and/or pain. 
The total volume of blood drawn during the entire study per study participant is estimated at 
approximately 450mL. No health-related risk to healthy study participants is expected from this 
blood withdrawal. 
Drug-related risks and safety measures 
Bimekizumab has a generally favorable clinical safety profile, and the drug is not associated with 
serious adverse events (SAEs) that would suggest a high risk to study participants in this study. 
The main safety concerns associated with bimekizumab include an increase in the risk for 
infection, in particular nonserious upper respiratory tract infections. Other types of nonserious 
infections (gastrointestinal, ear infection, conjunctivitis, bronchitis, mucocutaneous fungal 
infections) have also been commonly reported. The risk to study participants in this study will be 
minimized by the enrollment of healthy adult study participants who will be exposed to 
bimekizumab 320mg, dosed only once, by the implementation of conservative eligibility criteria, 
and that all study participants will be screened for chronic infections, including tuberculosis 
(TB). 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of bimekizumab may be found in the current IB. 
2.3.1 
Risk assessment for coronavirus disease 2019 
Bimekizumab is a humanized, full-length IgG monoclonal antibody, with high affinity for both 
human IL-17A and IL-17F. While the risk related to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) or COVID-19 is unknown, a safety concern cannot be excluded 
based on bimekizumab being an immunomodulatory antibody and dual inhibitor of 2 cytokines. 
Interleukin-17 is a family of pleiotropic pro-inflammatory cytokines released by activated T cells 
in the epithelial mucosal barrier upon stimulation with IL-23, which is mainly secreted by 
activated dendritic cells, macrophages, or monocytes. Interleukin-17 is often associated with 
allergic responses and autoimmune diseases, such as psoriasis. Interleukin-17A and IL-17F are 
the best characterized members of the IL-17 family, and IL-17A and IL-17F seem to be 
differently expressed in different tissues. Interleukin-17 is pivotal in innate and adaptive immune 
reaction to bacterial and viral infection, but has controversial effects. Studies suggest that the 
infectious dose may act as a determining factor regarding the protective or pathologic role of 
IL-17 during viral infection and was associated with the exacerbated pathology following viral 
infections, such as Epstein Barr Virus in mice (Ohta et al, 2013). There is growing evidence that 
inhibition of IL-17 might be beneficial in patients with COVID-19 to reduce the cytokine storm 
that causes the acute respiratory distress syndrome and vascular destruction, and studies are 
currently being conducted with other IL-17 inhibitors to investigate a potential beneficial effect. 
Based on these assumptions, the study is feasible in the appropriate population of healthy study 
participants naïve for SARS-CoV-2 under the specific precaution that the study participant is 
unlikely to be infected. Therefore, risk of the study participants to be exposed to SARS-CoV-2 or 
to suffer from COVID-19 will be acceptable in comparison to the general population. However, 
the risk of exposure to infected people cannot be completely excluded as the participants may 
need to share public spaces and communal areas with other members of the public (eg, commute 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 26 of 83 
to the site) and have additional human contact (eg, with site staff and other participants of the 
clinical study). 
Measures to mitigate the additional risks caused by COVID-19 are: 
• This study will re-start enrolling only when the Sponsor and contract research organization 
(CRO) in collaboration deem it is safe to start the study. In addition, the study will not re-
start until the local confinement measures or other safety restrictions linked to the COVID-19 
pandemic are lifted by the local authorities. 
• Current national laws and local recommendations for prevention of pandemic will be strictly 
adhered to. 
• Study participants will be closely monitored for any signs and symptoms of COVID-19, 
including fever, dry cough, dyspnea, sore throat, and fatigue throughout the study. Once 
clinical signs of infection are reported by participants, the Investigator needs to determine 
whether samples can be collected and safety data can be recorded on site. If not, AEs and 
concomitant medications will be obtained via phone calls. Tympanic body temperature 
measurements during inhouse stay and outpatient visits will be implemented. 
• The Investigator will not dose participants upon identification of any signs of COVID-19 
infection within the previous 14 days. 
• Confirmation of COVID-19 by laboratory assessment will be conducted with approved tests: 
a SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction (RT-PCR) will be 
conducted on admission and participants with a negative test will be randomized. 
• The probability of virus transmission will be controlled as much as possible by: 
− Advice for study participants to adhere to local requirements for social distancing and to 
minimize potential exposure to and/or transmission of the virus that causes COVID-19.  
− All participants will be contacted by telephone 1 day prior to the indicated visit (as per 
the schedule of activities) for assessing COVID-19 symptoms and signs and will be asked 
not to attend the site in case of suspected infection. In addition, participants will be asked 
for any contact with a person who has tested positive for SARS-CoV-2. If applicable, 
participants will be referred to the local health care system for further follow up and 
treatment. 
− Physical distancing and person-to-person contact restrictions will be applied during site 
admission and inhouse confinement. 
− Personal protective equipment will be used by study participants (eg, surgical face mask, 
gloves) and staff (for example but not limited to masks, gloves, protectors, medical suits) 
as guided by local requirements. 
− Logistical improvements of the site and structural measures of the study site building will 
be implemented to further improve physical distancing. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 27 of 83 
3 
OBJECTIVES AND ENDPOINTS 
Objectives 
Endpoints 
Primary 
To compare the PK of bimekizumab 320mg when 
administered sc using the bimekizumab-SS-2mL 
presentation (test 1) versus the bimekizumab-SS-1mL 
presentation (reference 1) or the bimekizumab-AI-2mL 
presentation (test 2) versus the bimekizumab-AI-1mL 
presentation (reference 2) in healthy study participants 
AUC, AUC(0-t), Cmax 
Secondary 
To assess 
• safety and tolerability 
• additional PK parameters 
of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL or 
bimekizumab-AI-2mL presentation in healthy study 
participants 
 
• TEAEs and treatment-emergent 
SAEs 
• t½, tmax 
Other/Exploratory 
To assess 
• additional PK parameters 
• immunogenicity 
• additional safety and tolerability 
of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL or 
bimekizumab-AI-2mL presentation in healthy study 
participants 
 
• %AUCex, CL/F, Vz/F 
• Incidence of bimekizumab 
antidrug antibodies 
• Vital signs (pulse rate, BP, and 
tympanic body temperature) 
• Safety laboratory data 
(hematology [including 
coagulation/hemostasis tests], 
clinical chemistry, and 
urinalysis) 
• 12-lead ECG assessments 
AE=adverse event; AI=auto-injector; AUC=area under the plasma concentration-time curve from time zero to 
infinity; %AUCex=percentage of the AUC extrapolated from Clast; AUC(0-t)=area under the plasma 
concentration-time curve from time zero to the last observed quantifiable concentration; BP=blood pressure; 
CL/F=apparent total body clearance; Clast=last observed quantifiable plasma drug concentration; 
Cmax=maximum observed plasma drug concentration; ECG=electrocardiogram; PK=pharmacokinetic; 
SAE=serious adverse event; SS=safety syringe; TEAE=treatment-emergent adverse event; t1/2=apparent 
terminal half-life; tmax=time of occurrence of Cmax; Vz/F=apparent volume of distribution 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 28 of 83 
4 
STUDY DESIGN 
4.1 
Overall design 
This is a Phase 1, open-label, single-center, randomized, parallel-group, single-dose, 4 arm BE 
study to compare the PK of bimekizumab 320mg when administered as either a 1x2mL or 
2x1mL sc injection in healthy male and female study participants. The SS and AI device 
presentations will be assessed. The 4 arms will be: 
1. bimekizumab-SS-2mL (test 1) 
2. bimekizumab-SS-2x1mL (reference 1) 
3. bimekizumab-AI-2mL (test 2) 
4. bimekizumab-AI-2x1mL (reference 2) 
Two independent comparisons will be made: test 1 versus reference 1 and test 2 versus 
reference 2. 
Four hundred healthy male and female study participants will participate in the study 
(approximately 100 study participants in each of 4 arms). Each study participant will receive a 
single-dose administration of bimekizumab 320mg. The duration of the study will be 
approximately 168 days, including 27 days of Screening, admission on Day -1, an inhouse 
Treatment Period from Day 1 to Day 3, Outpatients Visits until Day 112, and a Safety 
Follow-Up (SFU) Visit on Day 140. Randomization will occur on Day 1 prior to dosing. 
4.2 
Scientific rationale for study design 
The study design for this study is based on the recommendation of the guideline on the 
investigation of BE and the feedback received from the European Medicine Agency (EMA) in 
the Scientific Advice procedure EMEA/H/SA/3306/1/FU/1/2017/III (Sep 2017) on the 1mL 
device presentations. The parallel design was chosen with regard to the long half-life of 
bimekizumab of approximately 28 days. 
UCB is developing 4 self-injection, single-use, device presentations (bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL, and bimekizumab-AI-2mL) to provide patients 
with needle-safe injection options. The bimekizumab-SS offers control over the injection process 
(eg, needle visibility, skin penetration by needle, speed of injection) while the bimekizumab-AI 
offers a more automated injection. The 2mL device presentations are being introduced in this 
study to allow for the administration of bimekizumab 320mg as a single sc dose as opposed to 
the 2 injections required when using the 1mL device presentations. The aim of this study is to 
demonstrate the BE of bimekizumab administered as either 1x2mL or 2x1mL sc injections using 
the bimekizumab-SS and the bimekizumab AI in healthy study participants. 
The study design is deemed appropriate for conduct in healthy study participants during the 
COVID-19 pandemic (see Section 2.3.1 for details). 
4.3 
Justification for dose 
The dose selected in this study is the dose being used in the pivotal Phase 3 studies in PSO. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 29 of 83 
4.4 
End of study definition 
A study participant is considered to have completed the study if he/she has completed all phases 
of the study including the Day 140 SFU Visit or the last scheduled procedure shown in the 
schedule of activities (Section 1.3). 
The end of the study is defined as the date of the last scheduled procedure shown in the schedule 
of activities for the last study participant in the study. 
5 
STUDY POPULATION 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 
Inclusion criteria 
Study participants are eligible to be included in the study only if all of the following criteria 
apply: 
Age 
1. Study participant must be ≥18 years and ≤65 years of age inclusive, at the time of signing the 
informed consent. 
Type of study participant and disease characteristics 
2a. Study participants who are overtly healthy as determined by medical evaluation including 
medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and 
laboratory tests, during the Screening Visit and on admission. 
3a. Study participant has a tympanic body temperature between 35.0°C and 37.5°C, inclusive, at 
Screening and on admission. 
Weight 
4. Body weight minimum of 50kg for male and 45kg for female study participants and a 
maximum of 100kg for all study participants, and BMI within the range 18 to 32kg/m2 
(inclusive) at the Screening Visit. 
Sex 
5. Male or female. Contraception guidelines (as per the standard UCB contraceptive guideline) 
will be applicable. 
− A male study participant must agree to use contraception as detailed in Appendix 4 
(Section 10.4) of this protocol during the inhouse treatment period and for at least 
20 weeks after the administration of IMP (anticipated 5 half-lives), and refrain from 
donating sperm during this period. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 30 of 83 
− A female study participant is eligible to participate if she is not pregnant (see 
Appendix 4; Section 10.4), not breastfeeding, and at least one of the following conditions 
applies: 
◦ 
Not a woman of childbearing potential (WOCBP) as defined in Appendix 4 
OR 
◦ 
A WOCBP who agrees to follow the contraceptive guidance in Appendix 4 during the 
inhouse treatment period and for a period of 20 weeks after the administration of 
IMP. 
Informed consent 
6. An Independent Ethics Committee (IEC)-approved written Informed Consent Form (ICF) is 
signed and dated by the study participant prior to the initiation of any study-specific 
assessment at the Screening Visit, as described in Appendix 1 (Section 10.1.3). 
5.2 
Exclusion criteria 
Study participants are excluded from the study if any of the following criteria apply: 
Medical conditions 
1. Study participant has any medical or psychiatric condition that, in the opinion of the 
Investigator, could jeopardize or would compromise the study participant’s ability to 
participate in this study. 
2. Study participant has a history of chronic alcohol or drug abuse within 1 year prior to the 
Screening Visit. 
3. Study participant has a known hypersensitivity to any excipients of bimekizumab (and/or an 
investigational device) as stated in this protocol. 
4. Study participant has cardiovascular or cerebrovascular disease, including hypertension, 
angina, ischemic heart disease, transient ischemic attacks, stroke, peripheral arterial disease 
sufficient to cause symptoms, and/or requires therapy to maintain stable status. 
5. Study participant has an active infection or history of infections as follows: 
− Any active infection (except common cold) within 14 days prior to the Screening Visit 
− A serious infection, defined as requiring hospitalization or iv anti-infectives within 
2 months prior to the Screening Visit 
− A history of opportunistic, recurrent, or chronic infections that, in the opinion of the 
Investigator, might cause this study to be detrimental to the study participant. 
Opportunistic infections are infections caused by uncommon pathogens (eg, 
pneumocystis jirovicii, cryptococcosis) or unusually severe infections caused by common 
pathogens (eg, cytomegalovirus, herpes zoster). 
6. Study participant has a history of a positive TB test or evidence of possible TB or latent TB 
infection at the Screening Visit. Refer to g-q-100573 Tuberculosis Detection Procedure 
Guideline for details regarding TB infection status, detection procedures, and the related 
exclusion criteria. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 31 of 83 
7. Study participant has concurrent acute or chronic viral hepatitis B or C or human 
immunodeficiency virus (HIV) infection. Study participants who have evidence of, or tested 
positive for hepatitis B or hepatitis C are excluded. A positive test for the hepatitis B virus 
(HBV) is defined as: 
− positive for hepatitis B surface antigen (HBsAg+), or 
− positive for anti-hepatitis B core antibody (HBc-Ab+) (IgM). 
A positive test for the hepatitis C virus (HCV) is defined as: 
− positive for hepatitis C antibody (anti-HCV-Ab), and 
− positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction). 
8. Study participant has any of the following hematology values at the Screening Visit or on 
Day -1: 
− For women, hemoglobin <10.5g/dL; for men, <13.0g/dL 
− Absolute neutrophil count <1.5x109/L. 
9. Study participant has >1.5x upper limit of normal (ULN) of any of the following (which may 
be confirmed by repeat testing): alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP), or total bilirubin (≥1.5xULN total bilirubin if known 
Gilbert’s syndrome). If a study participant has elevations only in total bilirubin that are 
>ULN and <1.5xULN, bilirubin will be fractionated to identify possible undiagnosed 
Gilbert’s syndrome (ie, direct bilirubin <35%). 
10. Study participant has 12-lead ECG with changes considered to be clinically significant (eg, 
QT interval corrected using Fridericia’s formula [QTcF] >450ms, bundle branch block, or 
evidence of myocardial ischemia) at the Screening Visit or on Day -1. 
11. Study participant has abnormal blood pressure (BP) at the Screening Visit and on Day -1 as 
follows: mean systolic BP ≥140mmHg; mean diastolic BP ≥90mmHg. Participants with a BP 
within this range but who, in the opinion of the Investigator, have a high risk for 
cardiovascular accident based on, eg, family anamneses, smoking, BMI, or lipid spectrum 
can be excluded. 
12. Study participant has active neoplastic disease or history of neoplastic disease within 5 years 
of the Screening Visit (except for basal or squamous cell carcinoma of the skin or carcinoma 
in situ that has been definitively treated with standard of care). 
Prior/concomitant therapy 
13. Study participants receiving any live (includes attenuated) vaccination within the 8 weeks 
prior to the Screening Visit (eg, inactivated influenza and pneumococcal vaccines are 
allowed but nasal influenza vaccination is not permitted). Live vaccines are not allowed 
during the study or for 20 weeks after the dose of the IMP. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 32 of 83 
Prior/concurrent clinical study experience 
14. Study participant has previously participated in this study or the study participant has 
previously been assigned to treatment in a study of the medication under investigation in this 
study. 
15. Study participant has received any investigational drug or experimental procedure within 
90 days or 5 half-lives, whichever is longer, prior to IMP administration. 
Other exclusions 
16. Study participant has made a blood donation of a blood loss of more than 400mL of blood or 
blood products within 90 days prior to admission (Day -1) or plans to donate blood during 
the study. 
17. Female study participant is pregnant, or plans to become pregnant during the study, or is 
lactating, or sexually active with childbearing potential and is not using a medically accepted 
birth control method (see Appendix 4). 
18. Study participant has an alcohol consumption of more than 21 units (males) or 14 units 
(females) of alcohol per week [1 unit of alcohol is equivalent to 10mL ethanol, for example 
330mL of 5% alcohol by volume beer = 1.7 units; 125mL of 12% wine = 1.5 units; 50mL of 
spirits = 2 units]. 
19. Study participant tests positive for alcohol or drugs (urine tests) at Screening or Day -1. 
20. Study participant smokes >10 cigarettes per day or has a score of >4 on the Fagerström Test 
for Nicotine Dependence. 
21. Study participant has a high consumption of xanthine-containing products (≥300mg of 
xanthine-equivalent) [1 cup of coffee ≈ 100mg of caffeine; 1 cup of tea ≈ 30mg of caffeine; 
1 glass of cola ≈ 20mg of caffeine]. 
22. Study participant is not willing to avoid heavy physical exertion 48 hours before each 
assessment visit. 
23. Vulnerable participants (eg, participants kept in detention, protected adults under 
guardianship or trusteeship, and soldiers or participants committed to an institution by 
governmental or juridical order), employees of the Sponsor or the CRO with direct 
involvement in the proposed study or other studies under the direction of the Investigator or 
the CRO, as well as family members of the employees or the Investigator. 
24. Study participant has a positive test result for SARS-CoV-2 in RT-PCR on the admission 
sample. 
25. Study participant has clinical signs and symptoms consistent with COVID-19, eg fever, dry 
cough, dyspnea, sore throat, fatigue, or confirmed infection by appropriate laboratory test 
within the previous 14 days prior to Screening or on admission. 
26. Study participant who had severe course of COVID-19 (ie, hospitalization, extracorporal 
membrane oxygenation, mechanically ventilated). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 33 of 83 
5.3 
Lifestyle restrictions 
5.3.1 
Meals and dietary restrictions 
No specific dietary restrictions are required. 
5.3.2 
Caffeine, alcohol, and tobacco 
Study participants should refrain from consuming alcohol, caffeine, and tobacco during the 
inhouse treatment period. 
5.3.3 
Activity 
Study participants should abstain from strenuous exercise for at least 48 hours before each blood 
collection for clinical laboratory tests. Study participants may engage in light recreational 
activities during the study. 
5.3.4 
Other restrictions 
Due to the exceptional circumstance of the evolving COVID-19 pandemic, study participants are 
advised to adhere to local requirements while ambulatory, to minimize potential exposure to 
and/or transmission of the virus that causes COVID-19.  
All participants will be contacted 1 day prior to the indicated visit (as per the schedule of 
activities) for assessing COVID-19 symptoms and signs and will be asked not to attend the site 
in case of suspected infection.  
In addition, participants will be asked for any contact with a person who has confirmed infection.  
If applicable, participants will be referred to the local health care system. Physical distancing and 
person-to-person contact restrictions will be applied and explained to participants while staying 
at the study site.  
Where physical distancing is not possible, study participants will be asked to use surgical face 
masks and/or gloves if deemed appropriate by the Investigator and site staff and guided by local 
requirements. 
5.4 
Screen failures 
Screen failures are defined as study participants who consent to participate in the clinical study 
but are not subsequently randomly assigned to study treatment. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure study participants to 
meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, and any SAE. 
Individuals who do not meet the criteria for participation in this study (screen failures) may be 
rescreened following discussion with the UCB Study Physician (Section 5.5). 
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes rescreening. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 34 of 83 
5.5 
Rescreening 
Study participants may be rescreened once under conditions such as the following: 
• Study participant falls outside the Screening Period 
• If a study participant does not meet the inclusion criteria at Screening or on Day -1 due to an 
out-of-range laboratory result or a minor illness, he/she can be rescreened once at the 
discretion of the Investigator. Provided all inclusion criteria are met at the second screening, 
the study participant can be included. 
Study participants may be included if the repeat values for the laboratory screening criteria are 
within normal ranges and/or if repeat values show normalization of the out-of-range safety 
laboratory values, and/or after the study participant makes a complete recovery from the mild or 
moderate illness and if all other screening criteria are met. 
Rescreened study participants are assigned a new study participant number from the number 
assigned at the initial screening. 
6 
IMP/INVESTIGATIONAL DEVICE PRESENTATION 
(FUNCTIONAL SECONDARY PACKAGING) 
In this study, the term IMP refers to the bimekizumab drug product. The term device 
presentation refers to 4 different injection device presentations (bimekizumab-SS-1mL, 
bimekizumab-SS-2mL, bimekizumab-AI-1mL, and bimekizumab-AI-2mL) that are comprised of 
drug product (IMP) associated with a functional secondary packaging. 
Bimekizumab will be supplied by UCB Clinical Trial Supply Operations or designee as a clear to 
opalescent, colorless to slightly yellow-brown, sterile, preservative-free solution, suitable for 
injection by sc administration, in either a 1mL PFS or a 2mL PFS at a nominal concentration of 
160mg/mL (55mM sodium acetate, 220mM glycine, 0.04% polysorbate 80 at pH 5.0) for sc 
administration. 
6.1 
Treatments to be administered 
The treatments to be administered are presented in Table 6-1. 
Table 6-1: 
Treatments to be administered 
Study Treatment 
Bimekizumab-
SS-2mL 
Bimekizumab-
SS-1mL 
Bimekizumab-
AI-2mL 
Bimekizumab-
AI-1mL 
Drug product: 
2mL PFS 
1mL PFS 
2mL PFS 
1mL PFS 
All treatments: a nominal concentration of 160mg/mL in 55mM sodium acetate, 
220mM glycine and 0.04% (w/v) polysorbate 80 at pH5.0 
Total dose: 
320mg 
320mg 
320mg 
320mg 
Duration of 
treatment: 
Single dose 
Single dose 
Single dose 
Single dose 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 35 of 83 
Table 6-1: 
Treatments to be administered 
Study Treatment 
Bimekizumab-
SS-2mL 
Bimekizumab-
SS-1mL 
Bimekizumab-
AI-2mL 
Bimekizumab-
AI-1mL 
Number of 
injections: 
1x320mg 
2x160mg 
1x320mg 
2x160mg 
Route of 
administration 
sc 
sc 
sc 
sc 
Site of injection: 
Thigh (left or 
right) 
Thigh (1 in left 
and 1 in right) 
Thigh (left or 
right) 
Thigh (1 in left 
and 1 in right) 
Device 
presentation 
2mL SS 
1mL SS 
2mL AI 
1mL AI 
AI=auto-injector; PFS=prefilled syringe; sc=subcutaneous; SS=safety syringe 
The IMP will be given in the thigh without massage. For bimekizumab-SS-1mL, the injection 
should last approximately 10-15 seconds. For bimekizumab-AI-1mL, the injection should 
continue until a second click is heard (to give an injection time of up to 15 seconds). For the 
administration of the 2x1mL, each sc injection should be given in a separate thigh (but at the 
same relative site of the thigh) with a maximum time of 60 seconds between injections. The 
exact timing of the injection(s) should be recorded in the electronic Case Report Form (eCRF). 
For bimekizumab-SS-2mL, the injection should last approximately 15-20 seconds. For 
bimekizumab-AI-2mL, the full dose will be injected in approximately 20 seconds. 
Further details on how to proceed in the event of malfunction of any of the devices will be 
provided in the IMP handling manual. 
6.1.1 
Medical device presentations 
The device presentations provided for use in this study are the Nemera Safe’n’Sound SS device 
and the Ypsomed Ypsomate AI device. 
Instructions for medical device presentation use are provided in the respective Instructions for 
Use (IFU). 
All medical device presentation deficiencies, including malfunction use error, and inadequate 
labelling, shall be documented and reported by the Investigator throughout the study 
(see Section 8.3.7) and appropriately managed by the Sponsor. 
6.1.1.1 
Bimekizumab-SS 
The bimekizumab-SS is single-use PFS with a passive-needle safety mechanism. The 
bimekizumab-SS-1mL consists of a 1mL glass PFS and the bimekizumab-SS-2mL consists of a 
2mL glass PFS, both containing bimekizumab drug product within customized Nemera 
Safe’n’Sound device presentations. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 36 of 83 
Figure 6-1: Bimekizumab-SS-1mL 
 
SS=safety syringe 
Figure 6-2: Bimekizumab-SS-2mL 
 
SS=safety syringe 
6.1.1.2 
Bimekizumab-AI 
The bimekizumab-AI is single-use AI with a passive-needle safety feature. The 
bimekizumab-AI-1mL consists of a 1mL glass PFS and the bimekizumab-AI-2mL consists of a 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 37 of 83 
2mL glass PFS, both containing bimekizumab drug product within a customized Ypsomed 
Ypsomate device presentation. 
Figure 6-3: Bimekizumab-AI-1mL 
 
AI=auto-injector 
Figure 6-4: Bimekizumab-AI-2mL 
 
AI=auto-injector 
6.2 
Preparation, handling, storage, and accountability requirements 
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study treatment received and any discrepancies are reported and 
resolved before use of the study treatment. 
Only study participants enrolled in the study may receive study treatment and only authorized 
site staff may supply or administer study treatment. All study treatments must be stored in a 
secure, environmentally controlled, and monitored (manual or automated) area in accordance 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 38 of 83 
with the labeled storage conditions with access limited to the Investigator and authorized site 
staff. 
The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study treatment accountability, reconciliation, and record maintenance 
(ie, receipt, reconciliation, and final disposition records). 
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual. 
Appropriate accountability forms that reflect the receipt and use of the IMP and the 
investigational device presentations including IMP will be supplied to the investigational site. 
Details of any loss of the IMP and/or injection investigational device presentations due to 
breakage or wastage, non-use, destruction at the study site, or return to the Sponsor or designee 
must also be recorded on these forms. All supplies and pharmacy documentation must be made 
available throughout the study for UCB (or designee) to review. 
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
IMP and investigational device presentations until returned or destroyed. The Investigator may 
assign some of the Investigator’s duties for drug accountability at the study site to an appropriate 
pharmacist/designee. 
The device presentations should be stored with a proper study participant identification number 
until the study has been completed. UCB will then instruct the Investigator to destroy them. Used 
device presentations can be stored at room temperature, preferably placed in the original 
packaging. Further details are provided in the IMP Handling Manual. 
The IMP and investigational device presentations intended for the study cannot be used for any 
other purpose than that described in this protocol. 
6.2.1 
Retention samples 
The retention samples needed on site will represent 5 times the quantity needed to perform all 
release tests required; 500 samples will be retained. Sufficient quantities of each formulation will 
be provided to the sites for retention and study conduct purposes. 
Retention samples will be chosen at random by the Investigator and will be kept on site as 
retention samples to comply with Food and Drug Administration requirements Code of Federal 
Regulations (CFR)320, parts 38 and 63. 
6.3 
Measures to minimize bias: randomization and blinding 
This is an open-label study. 
A PAREXEL Biostatistician will write the randomization program and will provide a dummy 
output of the randomization for review in order to ensure compliance to study requirements. 
Study participant treatment assignment will be random throughout the study. Study participants 
will be randomized in a 1:1:1:1 ratio to each treatment group as described in Section 4.1. 
Copies of the randomization list will be sent before the start of the study to the following 
recipients: 
• ClinBase TM setup designer 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 39 of 83 
• Sponsor Drug Safety staff for SAE reporting 
• Bioanalytical staff 
• Site pharmacist and Pharmaceutical Services staff (for dispensing IMP) 
Pharmacokinetic concentration data will not be available to the study team until after the last 
scheduled procedure for the last study participant in the study, so the decision to replace 
participants who dropped out or are missing PK visits due to COVID-19 can be made in an 
unbiased manner.  
At the Screening Visit, each study participant will be assigned a unique 5-digit number from a 
range of numbers supplied by UCB. Once the Investigator determines that the study participant 
is eligible for the study, the study participant will be manually assigned to the next available 
randomization number by the Investigator or designee on the evening of Day -1. Each specific 
randomization number is tied to the treatment allocation on the randomization schedule, which 
can then be dispensed by the site pharmacist. This randomization number will also be recorded in 
the eCRF (ie, ClinBase; see Section 10.1.6). 
The study design accounts for a 10% rate of dropouts and/or nonevaluable participants 
(participants with missing PK visits that are expected to impact derivation of Cmax and/or AUC). 
The dropout rate will be closely monitored and if this 10% rate is likely to be exceeded, due to 
unforeseen circumstances during the COVID-19 pandemic, then participants may be replaced. 
The number of replacements will be discussed and agreed with the Sponsor. Replacement 
participants will be assigned the next available randomization number. 
6.4 
Treatment compliance 
All IMP will be administered by the Investigator or his/her appropriately trained designee. 
6.5 
Concomitant medication(s)/treatment(s) 
6.5.1 
Permitted concomitant treatments (medications and therapies) 
The following concomitant medications are permitted during the study: 
• Acetaminophen/paracetamol (maximum 2g/day) 
• Oral contraceptives  
• Hormonal postmenopausal treatment 
• Herbal remedy or food supplements (eg, vitamins) within the recommended daily dose limits 
• Short-term intake of over-the-counter/non-prescription drugs is allowed if judged by the 
Investigator to have no potential for drug-drug interactions with the IMP 
6.5.2 
Prohibited concomitant treatments (medications and therapies) 
With the exception of those medications listed in Section 6.5.1 and medications necessary for the 
treatment of TEAEs per Investigator discretion, no prescription or nonprescription medicines are 
allowed within 30 days (or 5 half-lives of the respective medication, whichever is longer) prior to 
randomization and until the SFU Visit (Day 140). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 40 of 83 
6.6 
Dose modification 
Not applicable. 
6.7 
Treatment after the end of the study 
Not applicable. 
7 
DISCONTINUATION OF STUDY MEDICATION AND STUDY 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
7.1 
Discontinuation of IMP 
Not applicable; eligible study participants are randomized to receive a single-dose administration 
of bimekizumab 320mg in UP0068. 
7.1.1 
Criteria for study hold due to adverse events 
During the study, planned dosing and procedures must be discontinued or suspended for all 
remaining study participants not yet dosed in the study and appropriate follow-up procedures 
established for (but not limited to) any of the following reasons: 
• A pattern of AEs, considered as related to the study drug, occurs that in the opinion of the 
Investigator and/or UCB Study Physician contraindicates the further dosing of additional 
study participants. 
• If the Sponsor or its designee judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations, and Good Clinical Practice (GCP). 
Where it is possible to do so without threatening the safety of study participants, such 
discontinuation/suspension should be discussed with the UCB Study Physician prior to its 
implementation. 
7.2 
Study participant discontinuation/withdrawal from the study 
Study participants are free to withdraw from the study at any time, without prejudice to their 
continued care and without having to provide any reason. 
A study participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or 
administrative reasons. 
If the study participant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent. 
If a study participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records. 
See the schedule of activities for data to be collected at the time of study discontinuation and 
follow-up and for any further evaluations that need to be completed. 
Study participants should be discontinued from the study if any of the following events occur: 
1. Study participant develops an illness that would interfere with his/her continued participation 
as per the Investigator’s judgment. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 41 of 83 
2. Study participant is noncompliant with the study procedures in the opinion of the 
Investigator. 
3. Study participant takes prohibited concomitant medications as defined in this protocol. 
4. Study participant withdraws his/her consent. 
5. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test. 
6. The Sponsor or a regulatory agency requests withdrawal of the study participant. 
7. Participation in any other study during the duration of this study. 
Participants must be withdrawn by the Investigator based on discussion with the Sponsor under 
the following circumstances: 
• Any confirmed COVID-19 case that warrants discontinuation in the judgment of the 
Investigator or Sponsor to protect the safety of the participant, other participants, or study site 
staff. 
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a study participant in advance. Study participants will be encouraged to return for a Safety 
Follow-up Visit following premature discontinuation from the study. 
7.3 
Lost to follow up 
A study participant will be considered lost to follow up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site. 
The following actions must be taken if a study participant fails to return to the clinic for a 
required study visit: 
• The site must attempt to contact the study participant and reschedule the missed visit as soon 
as possible and counsel the study participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the study participant wishes to and/or should 
continue in the study. 
• Before a study participant is deemed lost to follow up, the Investigator or designee must 
make a reasonable effort to regain contact with the study participant (at least 1 phone call and 
1 written message to the study participant), and document his/her effort (date and summary 
of the phone call and copy of the written message in the source documents), to complete the 
final evaluation. All results of these evaluations and observations, together with a narrative 
description of the reason(s) for removing the study participant, must be recorded in the 
source documents. The eCRF must document the primary reason for withdrawal. 
Should the study participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow up documented in the eCRF. 
8 
STUDY ASSESSMENTS AND PROCEDURES 
Study procedures and their timing are summarized in the schedule of activities (Section 1.3). 
Protocol waivers or exemptions are not allowed. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 42 of 83 
Adherence to the study design requirements, including those specified in the schedule of 
activities (Section 1.3), is essential and required for study conduct. 
All screening evaluations must be completed and reviewed to confirm that potential study 
participants meet all eligibility criteria. The Investigator will maintain a screening log to record 
details of all study participants screened and to confirm eligibility or record reasons for screening 
failure, as applicable. 
The maximum amount of blood collected from each study participant over the duration of the 
study, including any extra assessments that may be required, will not exceed 450mL. Repeat or 
unscheduled samples may be taken for safety reasons or for technical issues with the samples. 
8.1 
Efficacy assessments 
Not applicable. 
8.2 
Safety assessments 
Planned time points for all safety assessments are provided in the schedule of activities 
(Section 1.3). 
8.2.1 
Physical examination 
Physical examinations will be performed as per Section 1.3. The physical examination will 
include general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; 
cardiovascular; gastrointestinal; musculoskeletal; hepatic; neurological (including limb reflexes); 
and mental status. Findings considered as clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs. 
A full physical examination will be performed at the Screening Visit, Day 3, and SFU Visit. On 
all other days a physical examination is planned, it will be performed symptom-driven (ie, in 
case of an AE). 
8.2.2 
Body weight and height 
Body weight will be measured with the study participant wearing no shoes and light clothing 
(weight should be recorded to one decimal place) according to the schedule of activities in 
Section 1.3. Height will only be measured at the Screening Visit. 
8.2.3 
Vital signs 
Vital signs (BP [systolic and diastolic], pulse rate, and tympanic body temperature) will be 
recorded before taking PK samples and with the study participant resting in the supine position 
for at least 3 minutes in a quiet setting without distractions (eg, television, cell phones). 
8.2.4 
Electrocardiograms 
Single 12-lead ECG will be obtained as outlined in the schedule of activities (see Section 1.3) 
using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, 
and QTc intervals. 
All ECG recordings should be taken before taking PK samples and with the study participant 
resting in the supine position for at least 3 minutes. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 43 of 83 
8.2.5 
Clinical safety laboratory assessments 
See Appendix 2 (Section 10.2) for the list of clinical laboratory tests to be performed and the 
schedule of activities (Section 1.3) for the timing and frequency. 
Laboratory data will be electronically captured by ClinBase, a software tool that ensures quality 
assurance and enables comprehensive capture of all relevant medical information gathered 
during the study (Section 10.1.6). The Investigator can assess the data in ClinBase and sign off 
on them electronically. 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by the Investigator or Medical Monitor. If such values do not 
return to normal/baseline within a period of time judged reasonable by the Investigator, the 
etiology should be identified and the Sponsor notified. 
All protocol-required laboratory assessments, as defined in Appendix 2 (Section 10.2), must be 
conducted in accordance with the laboratory manual and the schedule of activities (Section 1.3). 
If laboratory values from non-protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are considered 
clinically significant by the Investigator (eg, SAE or AE), then the results are to be captured in 
ClinBase. 
8.2.6 
Tuberculosis test 
Refer to g-q-100573, UCB Tuberculosis Detection Procedure Guideline for details regarding 
tuberculosis infection status, detection procedures, and the related exclusion criteria. 
A QuantiFERON®-TB PLUS GOLD test and a TB questionnaire will be performed at the 
Screening Visit to identify those study participants who have had TB or may have active or latent 
TB. Results of this test will be reported as positive, negative, or indeterminate. Study participants 
with a positive test result will not be included in the study. If the result is reported as 
indeterminate, then the test can be repeated once. If the repeat test result is reported as 
indeterminate, then the study participant will not be included in the study. 
8.2.6.1 
Tuberculosis questionnaire 
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed at the Screening Visit. The questionnaire 
will assist with the identification of study participant who may require therapy for TB. A study 
participant who answers “Yes” to the question “Has the study participant been in close contact 
with an individual with active TB, or an individual who has recently been treated for TB?” at 
Screening is excluded. A “Yes” response to any of the other questions within the questionnaire at 
Screening should trigger further careful assessment to determine if the study participant has 
latent TB or active TB (see exclusion criterion #6 Section 5.2). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 44 of 83 
8.3 
Adverse events and serious adverse events 
The definitions of device-related safety events, (adverse device effects [ADEs] and serious 
adverse device effects [SADEs]), can be found in Appendix 7. Device deficiencies are addressed 
in Appendix 7 (Section 10.7). 
Adverse events will be reported by the study participant. 
The Investigator and any designees are responsible for detecting, documenting, and recording 
events that meet the definition of an AE or SAE and remain responsible for following up AEs 
that are serious, considered related to the study treatment or study procedures, or that caused the 
study participant to discontinue the study (see Section 7). 
Confirmed and suspected cases of SARS-CoV-2 infection will be recorded as AEs (or SAE, as 
required). 
8.3.1 
Time period and frequency for collecting AE and SAE information 
All AEs and SAEs will be collected from the signing of the ICF and at the time points specified 
in the schedule of activities (Section 1.3). 
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the ICF), including any pretreatment and posttreatment periods required by the 
protocol, must be reported in the CRF even if no study medication was taken but specific study 
procedures were conducted. This includes all AEs not present prior to the initial visit and all AEs 
that recurred or worsened after the initial visit. 
All SAEs will be recorded and reported to the Sponsor or designee within 24 hours, as indicated 
in Appendix 4 (Section 10.4). The Investigator will submit any updated SAE data to the Sponsor 
within 24 hours of it being available. 
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each study participant, and to also inform study participants 
of the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study. 
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 (Section 10.3). 
8.3.2 
Method of detecting AEs and SAEs 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the study participant is the preferred method to inquire about 
AE occurrences. 
8.3.3 
Follow-up of AEs and SAEs 
After the initial AE/SAE report, the Investigator is required to proactively follow each study 
participant at subsequent visits/contacts. All SAEs, [and non-serious AEs of special interest (as 
defined in Section 8.3.6), will be followed until resolution, stabilization, the Investigator 
determines that it is no longer clinically significant, the event is otherwise explained, or the study 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 45 of 83 
participant is lost to follow up (as defined in Section 7.3). Further information on follow-up 
procedures is given in Appendix 3 (Section 10.3). 
8.3.4 
Regulatory reporting requirements for SAEs 
Prompt notification by the Investigator to the Sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of study participants and the safety of a 
study treatment under clinical investigation are met. 
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply with country-specific regulatory requirements relating to safety reporting to 
the regulatory authority, IEC, and Investigators. 
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and Sponsor policy and forwarded to 
Investigators as necessary. 
An Investigator who receives an Investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it 
along with the IB and will notify the IEC, if appropriate according to local requirements. 
8.3.5 
Pregnancy 
Details of all pregnancies in female study participants and, if indicated, female partners of male 
study participants will be collected after the start of the inhouse treatment period and for at least 
20 weeks after the administration of IMP (anticipated 5 half-lives). 
If a pregnancy is reported, the Investigator must immediately inform the Sponsor within 24 hours 
of learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section 10.4). 
The study participant should be withdrawn from the study as soon as pregnancy is known (by 
positive pregnancy test), and the following should be completed: 
• The study participant should return for an early discontinuation visit. 
• A Safety Follow-Up Visit should be scheduled 20 weeks after the date of administration of 
the study participant’s IMP. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, and ectopic pregnancy) are considered SAEs. 
8.3.6 
Adverse events of special interest 
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 46 of 83 
For bimekizumab, the following event requires immediate reporting (within 24 hours, regardless 
of seriousness) to UCB: 
• Hy’s Law 
− Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality (ie, without waiting for any additional etiologic investigations 
to have been concluded). Follow-up information should be reported if an alternative 
etiology is identified during investigation and monitoring of the study participant. 
8.3.6.1 
Other safety topics of interest 
Prespecified safety topics of interest for the study are: infections (serious, opportunistic, fungal 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major 
cardiovascular events, liver function test changes/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral, as appropriate). 
This is based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or findings from other medicines with a related 
mechanism of action. There are no specific AE reporting requirements for these topics; however, 
special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB) are in place. 
8.3.7 
Medical device– AEs (ADE s, UADEs, SAEs, and USADEs) and device 
presentation deficiencies 
Medical device presentations are being provided for use in this study. In order to fulfill 
regulatory reporting obligations worldwide, the Investigator is responsible for the detection and 
documentation of events meeting the definitions of incident or malfunction that occur during the 
study with such device presentations. 
Adverse events will be reported according to the ISO 14155:2011, while recognizing and 
following requirements including reporting timelines specified in other specific laws, 
regulations, directives, standards and/or guidelines as appropriate and as required by the 
countries in which the clinical investigation is conducted. 
The definition of a Medical Device Deficiency can be found in Appendix 7 (Section 10.7). 
Note: Events fulfilling the definition of an AE/SAE will also follow the processes outlined in 
Section 8.3.3 and Appendix 3 (Section 10.3). 
8.3.7.1 
Time period for detecting medical device presentation deficiencies 
Medical device presentation deficiencies or malfunctions of the device presentation that result in 
reportable events will be detected, documented, and reported on the date of IMP administration 
when the medical device presentation is used. 
The method of documenting Medical Device Deficiency is provided in Appendix 7. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 47 of 83 
8.3.7.2 
Follow-up of medical device presentation deficiencies 
Follow-up applies to all study participants, including those who discontinue the study. 
The Investigator is responsible for ensuring that follow up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the deficiency. 
New or updated information will be recorded on the originally completed form with all changes 
signed and dated by the Investigator. 
8.3.7.3 
Prompt reporting of medical device presentation deficiencies to the 
Sponsor 
Device presentation deficiencies will be reported to the Sponsor within 24 hours after the 
Investigator determines that the event meets the protocol definition of a medical device 
presentation deficiency. 
The Adverse Event and Device Deficiency Report Form will be sent electronically to the 
Sponsor. The Sponsor will be the contact for the receipt of medical device deficiency reports. 
8.3.7.4 
Regulatory reporting requirements for medical device presentation 
deficiencies 
The Investigator will promptly report all device deficiencies occurring with any medical device 
presentation used in the study in order for the Sponsor to fulfill the legal responsibility to notify 
appropriate regulatory authorities and other entities about certain safety information relating to 
medical device presentations being used in clinical studies. 
The Investigator, or responsible person according to local requirements (eg, the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to the 
reporting of device deficiencies to the IEC. 
8.4 
Safety signal detection 
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study participants, regulatory 
authorities, and IECs will be informed appropriately and as early as possible. 
The UCB Study Physician or medically qualified designee/equivalent will conduct an ongoing 
review of SAEs and perform ongoing SAE reconciliations in collaboration with the Patient 
Safety (PS) representative. 
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory, or ECG results) for which data will be periodically reviewed during the course 
of the study. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 48 of 83 
8.5 
Treatment of overdose 
For this study, any dose of bimekizumab greater than a single-dose administration of 320mg will 
be considered an overdose. Overdose events are only considered AEs or SAEs if there are 
associated clinical signs and symptoms. 
8.6 
Pharmacokinetics 
Whole blood samples will be collected for measurement of plasma concentrations of 
bimekizumab as specified in the schedule of activities (Section 1.3). Instructions for the 
collection and handling of biological samples will be provided by the Sponsor. The actual date 
and time (24-hour clock time) of each sample will be recorded. The overall blood volume to be 
drawn from each study participant participating in the study will not exceed 450mL, ie, the 
amount of a blood donation. 
Samples will be used to evaluate the PK of bimekizumab. 
Genetic analyses will not be performed on these blood samples. Study participant confidentiality 
will be maintained. At visits during which blood samples for the determination of multiple 
aspects of bimekizumab will be taken, one sample of sufficient volume can be used. 
All PK samples should be drawn from study participants after the ECG has been recorded and 
the vital signs, including BP, have been measured. The following PK parameters will be derived 
from the plasma concentrations of bimekizumab: 
• Area under the plasma concentration-time curve from time zero to infinity (AUC) 
• Area under the plasma concentration-time curve from time zero to the last quantifiable 
concentration (AUC[0-t]) 
• Maximum observed plasma drug concentration (Cmax) 
• Time of occurrence of Cmax (tmax) 
• Apparent terminal half-life (t½) 
• Apparent total body clearance (CL/F) after subcutaneous administration , calculated as 
dose/AUC 
• Apparent volume of distribution (Vz/F), calculated as CL/λz 
• Percentage of the AUC extrapolated from Clast (%AUCex) 
All PK analyses will be performed under the supervision of the Quantitative Clinical 
Pharmacology Department, UCB using validated software (Phoenix 64, Pharsight, a Certara 
Company, USA). 
Any changes in the timing or addition of time points for any planned study assessments must be 
documented and approved by the relevant study team member and then archived in the Sponsor 
and site study files, but will not constitute a protocol amendment. The IEC will be informed of 
any safety issues that require alteration of the safety monitoring scheme or amendment of the 
ICF. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 49 of 83 
Pharmacokinetic samples for concentration measurement of bimekizumab may be stored for a 
maximum of 5 years (or according to local regulations) following the last study participant’s last 
visit at a facility selected by the Sponsor. 
8.7 
Genetics 
Genetics are not evaluated in this study. 
8.8 
Pharmacodynamics 
Pharmacodynamic parameters are not evaluated in this study. 
8.9 
Biomarkers 
Biomarkers are not evaluated in this study. 
8.10 
Immunogenicity assessments  
Antibodies to bimekizumab will be evaluated in plasma samples collected from all study 
participants according to the schedule of activities (Section 1.3). Additionally, plasma samples 
should also be collected at the final visit from study participants who were withdrawn from the 
study. These samples will be tested by the Sponsor or Sponsor’s designee. 
Plasma samples will be screened for antibodies binding to bimekizumab and the titer of 
confirmed positive samples will be reported. Other analyses may be performed to verify the 
stability of antibodies to bimekizumab and/or further characterize the immunogenicity of 
bimekizumab. 
The detection and characterization of antibodies to bimekizumab will be performed using a 
validated assay method by or under the supervision of the Sponsor. Anti-drug-antibodies will be 
measured using a three-tiered assay approach: screening assay, confirmatory assay, and titration 
assay. Samples may be stored for a maximum of 5 years (or according to local regulations) 
following the last study participant’s last visit for the study at a facility selected by the Sponsor 
to enable further analysis of immune responses to bimekizumab. 
8.11 
Medical resource utilization and health economics 
Not applicable. 
9 
STATISTICAL CONSIDERATIONS 
A description of statistical methods follows and will be described in more detail in the Statistical 
Analysis Plan (SAP). 
9.1 
Definition of analysis sets 
The Enrolled Set (ES) will consist of all study participants who signed the ICF. 
The Randomized Set (RS) will consist of all randomized study participants. 
The Full Analysis Set (FAS) will consist of all randomized study participants who received full 
or partial IMP according to the treatment the study participants actually received. The FAS will 
be used for summaries of demographics, medical history, prior and concomitant medications, 
IMP exposure, and general safety outcomes such as AEs, laboratory parameters, vital signs, and 
ECGs. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 50 of 83 
The PK Concentration Set (PKCS) will be a subset of the FAS, consisting of those study 
participants that received at least 1 dose of IMP and have at least 1 reported plasma 
concentration. All participants in the PKCS will be included in the listings. Participants with no 
protocol deviations to impact observed concentrations will be included in summary tables and 
figures of concentration-time profiles.  
The PK Per-Protocol Set (PK-PPS) will be a subset of the FAS, consisting of those study 
participants who had no important protocol deviations affecting the PK variables and for whom a 
sufficient number of samples are available to determine at least 1 PK parameter. This analysis set 
will be used for all summaries and analyses of the PK parameters. 
9.2 
General statistical considerations 
All analyses will be performed using Statistical Analysis System® (SAS®) version 9.4 or later 
(SAS Institute, Cary, NC, USA). 
For continuous variables, summary statistics will include number of study participants, mean, 
median, standard deviation (SD), minimum, and maximum. Categorical endpoints will be 
summarized using number of study participants, frequency, and percentages. Missing data will 
not be imputed. 
If not otherwise stated, Baseline will be the last assessment prior to dosing. Measurement of 
specific Baseline values will be described in the SAP. 
9.3 
Planned efficacy/outcome analyses 
As efficacy is not evaluated in this study, there is no primary efficacy endpoint. 
9.4 
Planned outcome analyses 
9.4.1 
Analysis of the primary endpoints 
The PK analyses will be performed on the PK-PPS. 
The primary PK parameters (Cmax, AUC(0-t), and AUC) will be evaluated according to a 
univariate model of analysis of variance (ANOVA). The model will include treatment group as a 
fixed effect. The dependent variables will be logarithmically transformed prior to statistical 
testing, following the usual recommendations. Natural logarithms (ln) will be employed. The 
90% confidence interval (CI) of the adjusted geometric mean ratios will be calculated. Two 
independent comparisons will be made (ie, test 1 versus reference 1 and test 2 versus reference 
2). For each of the respective comparisons, BE will be concluded if the 90% CIs for the ratio of 
the respective comparison are fully included in the acceptance range from 0.8 to 1.25 for AUC, 
AUC(0-t), and Cmax. 
Sensitivity analyses may also be performed on the PK parameters. 
9.4.2 
Analysis of secondary PK parameters 
Additionally, a similar ANOVA will be also performed on log-transformed t½ to compare 
elimination characteristics between treatment groups (ie, test 1 versus reference 1 and 
test 2 versus reference 2). 
The point estimate and the 90% CI for the median treatment differences for tmax will be 
computed according to the Hodges-Lehmann’s method. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 51 of 83 
9.4.3 
Study participant disposition and characteristics 
The number of study participants who were enrolled and randomized into the study, in each 
analysis set, and who completed or prematurely discontinued the study, as well as the reason for 
discontinuation, will be presented by treatment and overall using frequency counts and 
percentages. In addition, listings will be provided for study discontinuation, study participant 
disposition, and study participant analysis sets. 
Study participant characteristics will include a summary and listing of the following: 
• Demographics (including sex, age, race, ethnicity, height, weight, BMI, and lifestyle) 
• Medical history 
• Prior and concomitant medications 
Concomitant medical procedures will only be listed. 
9.5 
Planned safety and immunogenicity analyses 
9.5.1 
Safety analyses 
All safety parameters will be listed by study participant and treatment group using the FAS. 
The incidence of treatment-emergent adverse events (TEAEs) will be determined by treatment 
group, where applicable. Absolute and relative frequencies for a given TEAE by preferred term 
as per the Medical Dictionary for Regulatory Activities (MedDRA®), as well as absolute and 
relative frequencies of individual TEAEs, will be determined within each treatment group and 
system organ class. Additional tables will summarize TEAEs by maximum event intensity and 
causal relationship with IMP per treatment group and overall. The actions taken for each TEAE, 
the time of onset of the TEAE after dosing, and the duration of each AE will be listed. The 
TEAEs leading to discontinuation and SAEs will also be summarized. 
For continuous laboratory variables, values and changes from Baseline will be summarized at 
each time point. For categorized values according to the reference range, shift tables from 
Baseline to each postdose time point will be presented for selected variables. Values outside the 
reference range will be flagged in the data listings. The reference ranges will be reported. 
Normal versus abnormal findings for the various ECG parameters and overall ECG will be 
analyzed as required, focusing on the identification of outliers and of any trends for changes 
following administration of IMP with respect to QT/QTcF. Descriptive statistics will be 
presented for ECG value and changes from Baseline over time. 
Descriptive statistics will be reported for all vital sign measurements (including systolic and 
diastolic BP, pulse rate, and tympanic body temperature). Measured values and changes from 
Baseline will be summarized for all study participants by time point. 
Abnormal findings in the physical examination will be presented in listings only. 
9.5.2 
Immunogenicity analyses 
Bimekizumab anti-drug antibody (ADAb) levels will be listed per study participant and 
summarized using summary tables and figures. The number (and percentage) of participants with 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 52 of 83 
first occurrence of treatment-induced ADAb positivity will also be summarized at each postdose 
visit. The immunogenicity analyses will be further detailed in the SAP. 
9.6 
Handling of protocol deviations 
No protocol deviation is permitted, either in retrospect or prospect. 
Important protocol deviations are identified as part of the data cleaning process in the Data 
Cleaning Plan (DCP). The objective of the data cleaning meeting will be to review and update (if 
necessary) the important protocol deviations in the DCP and discuss exclusion of study 
participants from analysis populations. 
Furthermore, overall trends in protocol deviations will be discussed at the Data Evaluation 
Meeting. Through this data cleaning and evaluation process, all decisions regarding important 
protocol deviations and exclusions from analysis populations will be made. Protocol deviations 
(eg, missing assessments or visits) related to COVID-19 will be listed separately. 
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the trial master file (TMF). 
After resolution of all issues, and documentation of all decisions, the database will be locked. 
9.7 
Handling of dropouts or missing data 
There will be no special procedures for handling missing data. All imputation of missing or 
partial dates for safety assessments, as well as handling values below the limit of quantification 
in the PK data, will be detailed in the SAP. 
9.8 
Planned interim analysis and data monitoring 
No formal interim analysis is planned for this study. 
9.9 
Determination of sample size 
This is a formal BE study to compare the PK of bimekizumab-SS-2mL (test 1) versus 
bimekizumab-SS-2x1mL (reference 1), and bimekizumab-AI-2mL (test 2) versus 
bimekizumab-AI-2x1mL (reference 2). Two independent comparisons will be made (ie, test 1 
versus reference 1 and test 2 versus reference 2). 
The between subject variability (CV%) observed in previous small studies following a 
single-dose administration of bimekizumab in healthy study participants (ie, UP0031, RA0124, 
UP0033, and UP0074) was 21% to 25% for AUC and 23% to 33% for Cmax. 
Assuming a geometric mean ratio of 0.9 between each pair of formulations and a between 
subject variability (CV%) of 33%, 93 study participants per group are required to assess BE 
(using an acceptance range of 0.8 to 1.25) with 80% power at the 5% significance level. In the 
event that the true mean ratio between each pair of formulations is 0.95, then with the same 
assumptions on variability and significance level there is >95% power to determine BE for that 
pair of formulations. 
Sample size estimation was performed using SAS software (version 9.4). 
Assuming a dropout rate and nonevaluable study participants of approximately 10%, 100 study 
participants per group for a total of 400 study participants are to be enrolled in the study. If this 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 53 of 83 
10% rate is likely to be exceeded, due to unforeseen circumstances during the COVID-19 
pandemic, then participants may be replaced.  
10 
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
10.1 
Appendix 1: Regulatory, ethical, and study oversight 
considerations 
10.1.1 
Regulatory and ethical considerations 
The study will be conducted under the auspices of an IEC, as defined in local regulations, 
International Council for Harmonisation (ICH)-GCP, and in accordance with the ethical 
principles that have their origin in the Declaration of Helsinki. 
The Investigator/UCB will ensure that an appropriately constituted IEC that complies with the 
requirements of the current ICH-GCP version or applicable country-specific regulations will be 
responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other study 
participant-related documents to be used for the study to the IEC for its review and approval. 
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IEC for the protocol. 
The Investigator will also promptly report to the IEC all changes in the study, all unanticipated 
problems involving risks to study participants or others, and any protocol deviations, to eliminate 
immediate hazards to study participants. 
The Investigator will not make any changes in the study or study conduct without IEC approval, 
except where necessary to eliminate apparent immediate hazards to the study participants. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IEC as 
allowed. 
As part of the IEC requirements for continuing review of approved studies, the Investigator will 
be responsible for submitting periodic progress reports to the IEC (based on IEC requirements), 
at intervals appropriate to the degree of study participant risk involved, but no less than once per 
year. The Investigator should provide a final report to the IEC following study completion. 
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
The appropriate IEC will also be informed by the Investigator or the Sponsor, as specified by the 
applicable regulatory requirements in each concerned country. Where applicable, Investigators 
are to provide the Sponsor (or its representative) with evidence of any such IEC notification. 
10.1.2 
Financial disclosure 
Insurance coverage will be handled according to local requirements. 
Finance and insurance are addressed in the Investigator and/or CRO agreements, as applicable. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 54 of 83 
10.1.3 
Informed consent process 
Study participant’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki. 
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the study participant in both oral and written form by the 
Investigator (or designee). Each study participant will have the opportunity to discuss the study 
and its alternatives with the Investigator. 
Prior to participation in the study, an IEC-approved, written ICF should be signed and personally 
dated by the study participant and by the person who conducted the informed consent discussion 
(Investigator or designee) prior to the initiation of any study-specific assessment at the Screening 
Visit. The study participant must receive a copy of the signed and dated ICF. As part of the 
consent process, each study participant must consent to direct access to his/her medical records 
for study-related monitoring, auditing, IEC review, and regulatory inspection. 
If the ICF is amended during the study, the Investigator (or the Sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IEC and use of the amended form. 
The study participant may withdraw his/her consent to participate in the study at any time. A 
study participant is considered as enrolled in the study when he/she has signed the ICF. An eCRF 
must not be started, nor may any study specific procedure be performed for a given study 
participant, without having obtained his/her written consent to participate in the study. 
10.1.4 
Data protection 
UCB staff (or designee) will affirm and uphold the study participant’s confidentiality. 
Throughout this study, all data forwarded to UCB (or designee) will be identified by the study 
participant’s randomization number. 
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
study participant’s primary medical records that directly concerns this study (including, but not 
limited to, laboratory test result reports, ECG reports, admission/discharge summaries for 
hospital admissions occurring during a participant’s study participation, and autopsy reports for 
deaths occurring during the study). 
The study participant must be informed that his/her personal study-related data will be used by 
the Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the study participant. 
The study participant must be informed that his/her medical records may be examined by 
Clinical Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IEC members, and by inspectors from regulatory authorities. 
10.1.5 
Committees structure 
Not applicable. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 55 of 83 
10.1.6 
Data quality assurance 
The Sponsor will supervise study initiation visits to verify the qualifications of the Investigators, 
inspect the facilities, and inform the Investigators of responsibilities and procedures for ensuring 
adequate and correct documentation. 
The Investigators must prepare and maintain adequate and accurate records of all observations 
and other data pertinent to the clinical study for each study participant. Frequent communication 
between the clinical unit and the Sponsor is essential to ensure that the safety of the study is 
monitored adequately. The Investigators will make all appropriate safety assessments on an 
ongoing basis. 
All aspects of the study will be carefully monitored with respect to GCP and standard operating 
procedures (SOPs) for compliance with applicable government regulations. The Study Monitor 
will be an authorized individual designated by the Sponsor. The Study Monitor will have access 
to all records necessary to ensure the integrity of the data and will periodically review the 
progress of the study with the Investigators. Remote monitoring visits may be conducted during 
the COVID-19 pandemic or under other exceptional circumstances as deemed appropriate to 
ensure study participants’ safety.  
The Investigator must permit study-related monitoring, audits, IEC review, and regulatory 
agency inspections and provide direct access to source data documents. 
The Sponsor or designee is responsible for the data management of this study including quality 
checking of the data. 
Study Monitors will perform ongoing source data verification to confirm that data entered into 
ClinBase by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements. 
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP/investigational device. These 
documents should be retained for a longer period, however, if required by the applicable 
regulatory requirement(s) or by an agreement with UCB (CPMP/ICH/135/95, 2002 
[Section 4.9.5]). The Investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study-related files to a 
location other than that specified in the Sponsor’s TMF. 
10.1.6.1 
Case Report form completion 
The Investigator is responsible for prompt reporting of accurate, complete, and legible data in 
ClinBase and in all required reports. 
Any change or correction to ClinBase after saving must be accompanied by a reason for the 
change. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 56 of 83 
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator. 
The Investigator should maintain a list of personnel authorized to enter data into ClinBase. 
10.1.6.2 
Apps 
Not applicable. 
10.1.7 
Data collection and source documents 
PAREXEL will use ClinBase to collect medical data during this study. 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area. 
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the study participant’s source documents. 
If source documents have been captured by ClinBase, they need to be electronically 
signed/stamped to indicate review by the Investigator/designee/delegate. 
The Investigator/designee will facilitate the process for enabling the monitor to compare the 
content of the printout and the data stored in the computer to ensure all data are consistent. 
10.1.8 
Study and site closure 
The Sponsor designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed. 
The Investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by the Sponsor or Investigator may include but are 
not limited to: 
• Failure of the Investigator to comply with the protocol, the requirements of the IEC or local 
health authorities, the Sponsor’s procedures, or GCP guidelines 
• Inadequate recruitment of study participants by the Investigator 
• Discontinuation of further IMP development 
The study must be discontinued if the positive evaluation or approval is withdrawn by the IEC or 
local health authority. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 57 of 83 
10.1.9 
Publication policy 
The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. 
This allows the Sponsor to protect proprietary information and to provide comments. 
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator will be designated by mutual agreement. 
Authorship will be determined by mutual agreement and in line with International Committee of 
Medical Journal Editors authorship requirements. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 58 of 83 
10.2 
Appendix 2: Clinical laboratory tests 
The tests detailed in Table 10-1 below will be performed at SYNLAB Analytics & Services 
(safety laboratory assessments) and Parexel International (urinalysis/urine drug screen). 
Protocol-specific requirements for inclusion or exclusion of study participants are detailed in 
Section 5.1 and Section 5.2 of this protocol. 
Additional tests may be performed at any time during the study as determined necessary by the 
Investigator or required by local regulations. 
Table 10-1: Protocol-required safety laboratory assessments 
Laboratory measurements 
Variables 
Serology/virology 
HbsAg, HBc-Ab (both IgG and IgM), HCV-Ab, HIV1-Ab, 
HIV1-Ag, HIV-2 Ab, SARS-CoV-2 RT-PCRa  
Hematology 
Complete blood count, ie, hemoglobin, hematocrit, RBC, 
WBC, WBC with differential, platelet count 
Coagulation/hemostasis 
Prothrombin time, aPTT  
Clinical chemistry 
Albumin, ALP, ALT, AST, GGT, creatine kinase, LDH, total 
bilirubin, BUN, creatinine, glucose, total cholesterol, LDL 
cholesterol, HDL cholesterol, triglycerides, electrolytes 
(sodium, potassium, chloride, total calcium), and total 
protein, FSH 
Urine (dipstick) b 
pH, protein, glucose, ketone, urobilinogen, bilirubin, blood, 
specific gravity, nitrite, and leukocytes 
Urine alcohol test/drug screen 
Ethanol will be measured using a urine alcohol test. 
Urine drug screen includes 
amphetamines/methamphetamines, barbiturates, 
benzodiazepines, tetrahydrocannabinol, cocaine, tricyclic 
antidepressants, phencyclidine, and morphine/opiates 
Pregnancy 
Prior to dosing, a serum pregnancy test (hCG) will be 
performed; post dosing the test may be performed in urine. 
The FSH test will be performed in postmenopausal women at 
the Screening Visit. 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle stimulating hormone; 
GGT=gamma glutamyltransferase; HBc-Ab=hepatitis B core antibody; HBsAg=hepatitis B surface antigen; 
hCG=human chorionic gonadotropin; HCV-Ab=hepatitis C virus antibody; HDL=high density lipoprotein; 
HIV=human immunodeficiency virus; HIV1/2-Ab=HIV1/2 antibody; HIV1-Ag=HIV1 antigen; LDH=lactate 
dehydrogenase; IgG=immunoglobulin G; IgM=immunoglobulin M; LDL=low density lipoprotein; RBC=red 
blood cell; RT-PCR=real-time reverse transcriptase polymerase chain reaction; SARS-CoV-2=severe acute 
respiratory syndrome coronavirus 2; WBC=white blood cell 
a Sample will be obtained via pharyngeal swab. 
b Upon a positive urine test for leukocytes, blood, nitrite, or protein, the Investigator may require further urine 
analysis, such as flow cytometry. Results of additional urine analyses will be included in the database. If the flow 
cytometry examination shows a different result than the urine dipsticks, the urine will be investigated by fully 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 59 of 83 
automated digital imaging where leukocytes, erythrocytes, and casts (cellular, granular, hyaline) in urine will be 
analyzed. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 60 of 83 
10.3 
Appendix 3: Adverse events – definitions and procedures for 
recording, evaluating, follow up, and reporting 
10.3.1 
Definition of AE 
AE Definition 
• 
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally 
associated with the use of IMP, whether or not considered related to the IMP. 
• 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of IMP. 
 
Events Meeting the AE Definition 
• 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECG, radiological scans, vital signs measurements), including those 
that worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator (ie, not related to progression of underlying disease). 
• 
Exacerbation of a chronic or intermittent pre-existing condition including either an increase in 
frequency and/or intensity of the condition. 
• 
New conditions detected or diagnosed after IMP administration even though it may have been 
present before the start of the study. 
• 
Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• 
Signs, symptoms, or the clinical sequelae of a suspected overdose of either IMP or a 
concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be 
reported regardless of sequelae. 
 
Events NOT Meeting the AE Definition 
• 
Any clinically significant abnormal laboratory findings or other abnormal safety assessments 
which are associated with the underlying disease, unless judged by the Investigator to be more 
severe than expected for the study participant’s condition. 
• 
The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the study participant’s 
condition. 
• 
Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the 
procedure is the AE. 
• 
Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospital). 
• 
Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 61 of 83 
10.3.2 
Definition of SAE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (eg, hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
A SAE is defined as any untoward medical occurrence that, at any dose: 
a. 
Results in death 
b. 
Is life-threatening 
The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the study participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically might 
have caused death, if it were more severe. 
c. 
Requires inpatient hospitalization or prolongation of existing hospitalization 
In general, hospitalization signifies that the study participant has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would 
not have been appropriate in the physician’s office or outpatient setting. Complications that occur 
during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious 
criteria, the event is serious. When in doubt as to whether “hospitalization” occurred or was necessary, 
the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is 
not considered an AE. 
d. 
Results in persistent disability/incapacity 
• 
The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions. 
• 
This definition is not intended to include experiences of relatively minor medical significance 
such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(eg, sprained ankle) which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption. 
e. 
Is a congenital anomaly/birth defect 
f. 
Is an important medical events: 
• 
Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be immediately 
life-threatening or result in death or hospitalization but may jeopardize the study participant or 
may require medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually be considered serious. 
• 
Examples of such events include, but are not limited to, potential Hy’s law, invasive or 
malignant cancers, intensive treatment in an emergency room or at home for allergic 
bronchospasm, blood dyscrasias, or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 62 of 83 
10.3.3 
Recording and follow up of AE and/or SAE 
AE and SAE Recording 
• 
When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostics reports) related 
to the event. 
• 
The Investigator will then record all relevant AE/SAE information in the eCRF. 
• 
It is not acceptable for the Investigator to send photocopies of the study participant’s medical 
records to UCB in lieu of completion of the UCB AE/SAE eCRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by 
UCB. In this case, all study participant identifiers, with the exception of the study participant 
number, will be redacted on the copies of the medical records before submission to UCB. 
• 
The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
Assessment of Intensity 
The Investigator will make an assessment of intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories: 
• 
Mild: An event that is easily tolerated by the study participant, causing minimal discomfort and 
not interfering with everyday activities. 
• 
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities. 
• 
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with a SAE. Severe is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe. 
• 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe (eg, a severe AE may be 
either serious or not serious, depending on whether these criteria are also met). 
The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) 
should be used as a supportive standardization instrument to evaluate AEs and SAEs but the final 
intensity grading by the Investigator must be mild, moderate, or severe. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 63 of 83 
Assessment of Causality 
• 
The Investigator is obligated to assess the relationship between IMP and each occurrence of 
each AE/SAE. 
• 
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The Investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to IMP administration will be considered and 
investigated. 
• 
The Investigator will also consult the IB and/or Product Information, for marketed products, in 
his/her assessment. 
• 
For each AE/SAE, the Investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality. 
• 
There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to UCB. 
• 
The Investigator may change his/her opinion of causality in light of follow-up information and 
send a SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AEs and SAEs 
• 
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by UCB to elucidate 
the nature and/or causality of the AE or SAE as fully as possible. This may include additional 
laboratory tests or investigations, histopathological examinations, or consultation with other 
health care professionals. 
• 
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the study participant is lost to follow up. 
This follow-up requirement applies to AEs, SAEs, and AEs of special interest. 
• 
If a study participant dies during participation in the study or during a recognized follow-up 
period, the Investigator will provide UCB with a copy of any post-mortem findings including 
histopathology. 
• 
New or updated information will be recorded in the originally completed eCRF. 
• 
The Investigator will submit any updated SAE data to the UCB within 24 hours of receipt of 
the information. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 64 of 83 
Reporting of SAEs 
SAE Reporting to UCB via an Electronic Data Collection Tool 
• 
The primary mechanism for reporting an SAE to UCB will be the electronic data collection tool. 
• 
If the electronic system is unavailable for more than 24 hours, then the site will use the paper SAE 
data collection tool (see next section). 
• 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
• 
After the study is completed at a given site, the electronic data collection tool will be taken off-line 
to prevent the entry of new data or changes to existing data. 
• 
If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off-line, then the 
site can report this information on a paper SAE form (see next bullet) or to the UCB Study 
Physician by telephone. 
• 
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 65 of 83 
10.4 
Appendix 4: Contraceptive guidance and collection of 
pregnancy information 
Definitions 
Woman of Childbearing Potential (WOCBP) 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below). 
Women in the following categories are not considered WOCBP: 
1. Premenarchal 
2. Premenopausal female with 1 of the following: 
− Documented hysterectomy 
− Documented bilateral salpingectomy 
− Documented bilateral oophorectomy 
Note: Documentation can come from the site personnel’s review of the study participant’s 
medical records, medical examination, or medical history interview. 
3. Postmenopausal female 
− A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, a 
single FSH measurement is insufficient. 
− Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to 
continue their HRT during the study. Otherwise, they must discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment. 
Contraception Guidance 
Male study participants 
Male study participants with female partners of childbearing potential are eligible to participate 
if they agree to ONE of the following for a period of 20 weeks after their dose of IMP. 
• Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent. 
• Agree to use a male condom plus partner use of a contraceptive method with a failure rate of 
<1% per year as described in Appendix 4 (Section 10.4) when having penile-vaginal 
intercourse with a woman of childbearing potential who is not currently pregnant. 
In addition, male study participants must refrain from donating sperm for the duration of the 
study and for at least 20 weeks after IMP administration. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 66 of 83 
Male study participants with a pregnant or breastfeeding partner must agree to remain abstinent 
from penile-vaginal intercourse or use a male condom during each episode of penile penetration 
during the protocol-defined time frame. 
Female study participants 
Female study participants of childbearing potential are eligible to participate if they agree to use 
a highly effective method of contraception consistently and correctly as described in Appendix 4 
(Section 10.4). 
Table 10-2: Highly effective contraceptive methods a 
Highly Effective Contraceptive Methods That Are User Dependentb 
Failure rate of <1% per year when used consistently and correctly. 
Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of 
ovulation c 
• 
Oral 
• 
Intravaginal 
• 
Transdermal 
Progestogen-only hormonal contraception associated with inhibition of ovulation 
• 
Oral 
• 
Injectable 
Highly Effective Methods That Are User Independentb 
Implantable progestogen-only hormonal contraception associated with inhibition of ovulation 
• 
Intrauterine device (IUD) 
• 
Intrauterine hormone-releasing system (IUS) 
• 
Bilateral tubal occlusion 
Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the woman of childbearing potential (WOCBP) and the absence of sperm has been 
confirmed. If not, an additional highly effective method of contraception should be used. 
Sexual abstinence 
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the investigational medicinal product (IMP). 
The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the study participant. 
a In case of newly started contraception pills/IUDs, PI should consider the correct timing of starting/applying such 
methods in relation to the menstrual cycle and the manufacturing instruction as when these newly started methods 
would become effective. 
b Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent with 
local regulations regarding the use of contraceptive methods for study participants participating in clinical studies. 
c Hormonal contraception may be susceptible to interaction with the IMP, which may reduce the efficacy of the 
contraceptive method. In this case, two highly effective methods of contraception should be utilized during the 
treatment period and for at least 20 weeks after IMP administration. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 67 of 83 
Pregnancy testing 
• WOCBP should only be included after a confirmed menstrual period and a negative highly 
sensitive serum pregnancy test. 
• Additional pregnancy testing should be performed at monthly intervals during the treatment 
period, and at the SFU Visit at Day 140. 
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected. 
• Pregnancy testing, with a sensitivity of 25mIU/mL will be performed. 
Male participants with partners who become pregnant 
• The Investigator will attempt to collect pregnancy information on any male study 
participant’s female partner who becomes pregnant while the male study participant is in this 
study and for at least 20 weeks after IMP administration. 
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 1 working day of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. Information 
on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow 
up will be at least 12 months after the delivery date. Any termination of the pregnancy will 
be reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure. 
Female participants who become pregnant 
• Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study. 
• The Investigator will collect pregnancy information on any female study participant who 
becomes pregnant while participating in this study. Information will be recorded on the 
appropriate form and submitted to the Sponsor within 24 hours of learning of a study 
participant’s pregnancy. The study participant will be followed to determine the outcome of 
the pregnancy. The Investigator will collect follow-up information on the study participant 
and the neonate and the information will be forwarded to the Sponsor. Generally, the follow 
up will be at least 12 months after the delivery date. Any termination of pregnancy will be 
reported, regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure. 
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy will be reported as an AE or SAE. A spontaneous 
abortion is always considered to be an SAE and will be reported as such. Any post-study 
pregnancy-related SAE considered reasonably related to the IMP by the Investigator will be 
reported to the Sponsor as described in Section 8.3.5. While the Investigator is not obligated 
to actively seek this information in former study participants, he or she may learn of an SAE 
through spontaneous reporting. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 68 of 83 
10.5 
Appendix 5: Genetics 
Not applicable. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 69 of 83 
10.6 
Appendix 6: Liver safety – suggested actions and follow-up 
assessments 
Study participants with PDILI should not be withdrawn from the study until investigation and 
monitoring are complete. All results of these evaluations and observations, as well as the 
reason(s) for study participant withdrawal (if applicable), must be recorded in the source 
documents. 
A specific monitoring plan must be agreed between the UCB Study Physician and the 
Investigator for study participants who have ALT >5 ULN. The monitoring plan should include 
any necessary follow-up assessments (until resolution of the abnormal lab values). 
Phase 1 liver chemistry stopping criteria are designed to assure study participant safety and to 
evaluate liver event etiology (Table 10-3). 
Table 10-3: Phase I liver chemistry stopping criteria and follow-up 
assessments 
Liver Chemistry Stopping Criteria – Liver Stopping Event 
ALT-absolute 
ALT≥3xULN 
If ALT ≥3xULN AND bilirubin 2xULN (>35% direct bilirubin) OR 
international normalized ratio (INR) >1.5, report as a serious adverse event 
(SAE).a,b 
See additional actions and follow-up assessments listed below. 
Suggested Actions and Follow up Assessments 
Actions 
Follow Up Assessments 
• Report the event to the UCB within 24 hours 
• Complete the liver event eCRF, and complete 
an SAE data collection tool if the event also 
met the criteria for an SAE. 
• Perform liver chemistry follow-up assessments. 
• Monitor the study participant until liver 
chemistry test abnormalities resolve, stabilize, 
or return to Baseline (see MONITORING). 
MONITORING: 
If ALT 3xULN AND bilirubin 2xULN or INR 
>1.5: 
• Repeat liver chemistry tests (include ALT, 
aspartate transaminase [AST], alkaline 
phosphatase, bilirubin) and perform liver event 
follow-up assessments within 24 hours. 
• Viral hepatitis serologyc 
• Obtain INR and recheck with each 
liver chemistry assessment until the 
transaminases values show 
downward trend 
• Serum creatine phosphokinase 
(CPK) and lactate dehydrogenase 
(LDH) 
• Fractionate bilirubin, if total 
bilirubin 2xULN 
• Obtain complete blood count with 
differential to assess eosinophilia 
• Record the appearance or worsening 
of clinical symptoms of liver injury, 
or hypersensitivity, on the AE eCRF 
• Record use of concomitant 
medications (including 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 70 of 83 
• Monitor study participant twice weekly until 
liver chemistry test abnormalities resolve, 
stabilize, or return to Baseline. 
• A specialist or hepatology consultation is 
recommended. 
If ALT ≥3xULN AND bilirubin <2xULN and INR 
≤1.5: 
• Repeat liver chemistry tests (include ALT, 
AST, alkaline phosphatase, bilirubin) and 
perform liver chemistry follow-up assessments 
within 24 to 72 hours. 
• Monitor study participants weekly until liver 
chemistry abnormalities resolve, stabilize, or 
return to Baseline. 
acetaminophen, herbal remedies, and 
other over-the-counter medications) 
on the concomitant medications 
eCRF. 
• Record alcohol use on the liver event 
alcohol intake eCRF. 
If ALT ≥3xULN AND bilirubin 
2xULN or INR >1.5: 
• Anti-nuclear antibody, anti-smooth 
muscle antibody, Type 1 anti-liver 
kidney microsomal antibodies, and 
quantitative total IgG or gamma 
globulins. 
• Serum acetaminophen adduct high 
performance liquid chromatography 
(HPLC) assay (quantifies potential 
acetaminophen contribution to liver 
injury in study participants with 
definite or likely acetaminophen use 
in the preceding week [James, 
2009].) 
• Liver imaging (ultrasound, magnetic 
resonance, or computerized 
tomography) and/or liver biopsy to 
evaluate liver disease; complete liver 
imaging and/or liver biopsy eCRFs. 
a Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation testing is 
unavailable, record the absence/presence of detectable urinary bilirubin on dipstick, which is indicative of direct 
bilirubin elevations suggesting liver injury. 
b All events of ALT ≥3xULN and bilirubin ≥2xULN (>35% direct bilirubin) or ALT ≥3xULN and INR >1.5 may 
indicate severe liver injury (possible ‘Hy’s Law’) and must be reported as SAEs (excluding studies of hepatic 
impairment or cirrhosis). The INR measurement is not required and the stated threshold value will not apply to 
study participants receiving anticoagulants. 
c Hepatitis A immunoglobulin M (IgM) antibody; HBsAg and HbcAb; hepatitis C ribonucleic acid; cytomegalovirus 
IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, heterophile antibody or monospot 
testing); and hepatitis E IgM antibody. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 71 of 83 
10.7 
Appendix 7: Medical device presentation AEs, ADEs, SAEs and 
Device Deficiencies: – definition and procedures for recording, 
evaluating, follow up, and reporting 
10.7.1 
Definitions of a medical device presentation incident 
The definitions and procedures detailed in this appendix are in accordance with ISO 14155. 
Both the Investigator and the sponsor will comply with all local medical device reporting 
requirements. 
The detection and documentation procedures described in this protocol apply to all Sponsor 
medical device presentations provided for use in the study. See Section 6.1.1 for the list of 
Sponsor medical device presentations. 
10.7.2 
Definition of AE and ADE 
AE and ADE Definition 
• An AE is defined as any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory finding) in study participants, 
users, or other persons, whether or not related to the investigational medical device. This 
definition includes events related to the investigational medical device or comparator and 
events related to the procedures involved except for events in users or other persons, which 
only include events related to investigational devices. 
• An adverse device effect (ADE) is defined as an adverse event related to the use of an 
investigational medical device. This definition includes any adverse events resulting from 
insufficient or inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device as well as any event 
resulting from use error or from intentional misuse of the investigational medical device. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 72 of 83 
10.7.3 
Definition of SAE, SADE and USADE 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to 
progression of disease). 
An SAE is an AE that: 
a. Led to death 
b. Led to serious deterioration in the health of the participant, that either resulted in: 
1. A life-threatening illness or injury. The term ‘life-threatening’ in the definition of serious’ 
refers to an event in which the participant was at risk of death at the time of the event. It does 
not refer to an event, which hypothetically might have caused death, if it were more severe 
2. A permanent impairment of a body structure or a body function, 
3. Inpatient or prolonged hospitalization, Planned hospitalization for a pre-existing condition, or a 
procedure required by the protocol, without serious deterioration in health, is not considered an 
SAE 
4. Medical or surgical intervention to prevent life-threatening illness or injury or permanent 
impairment to a body structure or a body function 
c. Led to fetal distress, fetal death or a congenital abnormality or birth defect 
SADE definition 
• 
A SADE is defined as an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event. 
USADE definition 
• 
A USADE is a serious adverse device effect which by its nature, incidence, severity, or 
outcome has not been identified in the current version of the risk analysis report (see 
Section 8.3.7). 
10.7.4 
Definition of device presentation deficiency 
Device presentation deficiency definition 
• 
A device presentation deficiency is an inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, safety, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate labeling. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 73 of 83 
10.7.5 
Recording and follow up of AE and/or SAE and device deficiencies 
AE, SAE and device deficiency recording 
• 
When an AE/SAE/device deficiency occurs, it is the responsibility of the Investigator to review 
all documentation (e.g., hospital progress notes, laboratory reports, and diagnostics reports) 
related to the event. 
• 
The Investigator will then record all relevant AE/SAE/device deficiency information in the 
participant’s medical records, in accordance with the Investigator’s normal clinical practice 
and on the appropriate form of the CRF. 
• 
It is not acceptable for the Investigator to send photocopies of the participant’s medical records 
to UCB in lieu of completion of the UCB /AE/SAE/device deficiency CRF page. 
• 
There may be instances when copies of medical records for certain cases are requested by [X]. 
In this case, all participant identifiers, with the exception of the participant number, will be 
redacted on the copies of the medical records before submission to UCB. 
• 
The Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information. Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE. 
• 
For device deficiencies, it is very important that the Investigator describes any corrective or 
remedial actions taken to prevent recurrence of the deficiency 
o A remedial action is any action other than routine maintenance or servicing of a 
medical device where such action is necessary to prevent recurrence of a device 
deficiency. This includes any amendment to the device design to prevent recurrence. 
The Investigator should complete a Product Complaint Form for all reported device 
deficiencies. 
Assessment of intensity 
The Investigator will make an assessment of intensity for each AE/SAE/device deficiency reported 
during the study and assign it to one of the following categories: 
• 
Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not 
interfering with everyday activities. 
• 
Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities. 
• 
Severe: An event that prevents normal everyday activities. An AE that is assessed as severe 
should not be confused with a SAE. Severe is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe. 
• 
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 74 of 83 
Assessment of causality 
• 
The Investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE/device deficiency 
• 
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
• 
The Investigator will use clinical judgment to determine the relationship. 
• 
Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, 
as well as the temporal relationship of the event to study intervention administration will be 
considered and investigated. 
• 
The Investigator will also consult the Investigator’s Brochure (IB) and/or Product Information, 
for marketed products, in his/her assessment. 
• 
For each AE/SAE/device deficiency, the Investigator must document in the medical notes that 
he/she has reviewed the AE/SAE/device deficiency and has provided an assessment of 
causality. 
• 
There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to UCB. However, it is very important that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to UCB. 
• 
The Investigator may change his/her opinion of causality in light of follow-up information and 
send a SAE follow-up report with the updated causality assessment. 
• 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements. 
 
Follow-up of AE/SAE/device deficiency 
• 
The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by UCB to elucidate 
the nature and/or causality of the AE/SAE/device deficiency as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals. 
• 
New or updated information will be recorded in the originally completed CRF. 
• 
The Investigator will submit any updated SAE data to UCB within 24 hours of receipt of the 
information. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 75 of 83 
10.7.6 
Reporting of SAEs 
SAE reporting to UCB via an electronic data collection tool 
• 
The primary mechanism for reporting an SAE to UCB will be the electronic data collection 
tool. 
• 
If the electronic system is unavailable, then the site will use the paper SAE data collection tool 
(see next section) in order to report the event within 24 hours. 
• 
The site will enter the SAE data into the electronic system as soon as it becomes available. 
• 
After the study is completed at a given site, the electronic data collection tool will be taken off-
line to prevent the entry of new data or changes to existing data. 
• 
If a site receives a report of a new SAE from a study participant or receives updated data on a 
previously reported SAE after the electronic data collection tool has been taken off-line, then 
the site can report this information on a paper SAE form (see next section) or to the UCB 
Medical Monitor by telephone. 
• 
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING. 
 
SAE reporting to UCB via paper 
• 
Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the UCB Medical Monitor. 
• 
In rare circumstances and in the absence of facsimile equipment, notification by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service. 
• 
Initial notification via telephone does not replace the need for the Investigator to complete and 
sign the SAE CRF pages within the designated reporting time frames. 
• 
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING. 
10.7.7 
Reporting of SADEs 
SADE Reporting to UCB 
NOTE: There are additional reporting obligations for medical device deficiencies that are potentially 
related to SAEs that must fulfil the legal responsibility to notify appropriate regulatory authorities and 
other entities about certain safety information relating to medical devices being used in clinical studies. 
• 
Any device deficiency that is associated with an SAE must be reported to the sponsor within 
24 hours after the Investigator determines that the event meets the definition of a device 
deficiency. 
• 
The sponsor shall review all device deficiencies and determine and document in writing 
whether they could have led to an SAE. These shall be reported to the regulatory authorities 
and IRBs/IECs as required by national regulations. 
• 
Contacts for SAE reporting can be found in SERIOUS ADVERSE EVENT REPORTING. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 76 of 83 
10.7.8 
AE, ADE, SAE, SADE determination flow chart 
Note: Adverse event reporting for countries other than the USA and EU must follow the 
regulatory and ethical requirements for that country. 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 77 of 83 
10.8 
Appendix 8: Rapid alert procedures 
Not applicable. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 78 of 83 
10.9 
Appendix 9: Country-specific requirements 
Not applicable. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 79 of 83 
10.10 
Appendix 10: Abbreviations and trademarks 
Ab 
antibody 
ADAb 
anti-drug antibody 
ADE 
adverse device effect 
AE 
adverse event 
AI 
auto-injector 
ALP 
alkaline phosphatase 
ALT 
alanine aminotransferase 
ANOVA 
analysis of variance 
AS 
ankylosing spondylitis 
ASADE 
anticipated serious adverse device effect 
AST 
aspartate aminotransferase 
AUC 
area under the plasma concentration-time curve from time zero to infinity  
%AUCex 
percentage of the AUC extrapolated from Clast 
AUC(0-t)  
area under the plasma concentration-time curve from time zero to the last 
quantifiable concentration 
axSpA 
axial spondyloarthritis 
BE 
bioequivalence 
BMI 
body mass index 
BP 
blood pressure 
CI 
confidence interval 
CFR 
Code of Federal Regulations 
CL/F 
apparent total body clearance  
Clast 
last observed quantifiable plasma drug concentration 
Cmax  
maximum observed plasma drug concentration 
COVID-19 
coronavirus disease 2019 
CPK 
creatine phosphokinase 
CV 
coefficient of variation 
DCP 
Data Cleaning Plan 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
ES 
Enrolled Set 
FAS 
Full Analysis Set 
FSH 
follicle stimulating hormone 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 80 of 83 
GCP 
Good Clinical Practice 
HBc-Ab 
anti-hepatitis B core antibody 
HbsAg 
hepatitis B surface antigen 
HBV 
hepatitis B virus 
HCV 
hepatitis C virus 
HIV 
human immunodeficiency virus 
HRT 
hormonal replacement therapy 
HS 
hidradenitis suppurativa 
IB 
Investigatorʼs Brochure 
ICF 
Informed Consent Form 
ICH 
International Council for Harmonisation 
IEC 
Independent Ethics Committee 
IFU 
Instructions for Use 
Ig 
immunoglobulin 
IL 
interleukin 
IMP 
investigational medicinal product 
LDH 
lactate dehydrogenase 
MedDRA® 
Medical Dictionary for Regulatory Activities 
PDILI 
potential drug-induced liver injury 
PFS 
prefilled syringe 
PK 
pharmacokinetics 
PKCS 
Pharmacokinetic Concentration Set 
PK-PPS 
Pharmacokinetic Per-Protocol Set 
PS 
Patient Safety 
PsA 
psoriatic arthritis 
PSO 
psoriasis 
QTcF 
QT interval corrected using Fridericia’s formula 
RA 
rheumatoid arthritis 
RS 
Randomized Set 
RT-PCR 
real-time reverse transcriptase polymerase chain reaction 
SADE 
serious adverse device effect 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 81 of 83 
SAS® 
Statistical Analysis System 
sc 
subcutaneous 
SD 
standard deviation 
SFU 
Safety Follow-Up 
SOP 
standard operating procedure 
SS 
safety syringe 
SUSAR 
suspected unexpected serious adverse reaction 
t½  
apparent terminal half-life 
TB 
tuberculosis 
TEAE 
treatment-emergent adverse event 
tmax 
time of occurrence of Cmax 
TMF 
trial master file 
UC 
ulcerative colitis 
ULN 
upper limit of normal 
USADE 
unanticipated serious adverse device effect 
Vz/F 
apparent volume of distribution 
WOCBP 
women of childbearing potential 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 82 of 83 
11 
REFERENCES 
Allison DJ, Ditor DS. The common inflammatory etiology of depression and cognitive 
impairment: a therapeutic target. J Neuroinflammation. 2014;11:151. 
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002. 
EMA. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
pandemic. Version 3. 28 Apr 2020. Available at: 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-
10/guidanceclinicaltrials_covid19_en.pdf  
EMEA/H/SA/3306/1/FU/1/2017/III Sep 2017. 
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009. 
ISO 14155:2011 Clinical Investigations of medical devices for human subjects – Good Clinical 
Practice. 
Ohta R, Imai M, Kawada J, Kimura H, Ito Y. Interleukin-17A-producing T lymphocytes in 
chronic active Epstein-Barr virus infection. Microbiol Immunol. 2013;57(2):139-44. 
Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on 
medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation 
(EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
24 Jul 2020 
Clinical Study Protocol 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 83 of 83 
SPONSOR DECLARATION 
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


Approval Signatures
Name:
UP0068-protocol-amend-1
Version:
1. 0
Document Number:
CLIN-000155300
Title:
UP0068 Protocol Amendment 1
Approved Date:
28 Jul 2020
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Medical
Date of Signature: 27-Jul-2020 09:34:40 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 27-Jul-2020 10:47:43 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Management Approval
Date of Signature: 27-Jul-2020 17:28:22 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 28-Jul-2020 10:11:53 GMT+0000
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.

SAP_001.pdf: 
UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 1 of 39 
 
STATISTICAL ANALYSIS PLAN 
Study: UP0068 
Product: Bimekizumab 
AN OPEN-LABEL, SINGLE-CENTER, RANDOMIZED, PARALLEL-GROUP, SINGLE-
DOSE BIOEQUIVALENCE STUDY OF BIMEKIZUMAB GIVEN AS 1X2ML OR 2X1ML 
SUBCUTANEOUS INJECTION IN HEALTHY STUDY PARTICIPANTS 
 
SAP/Amendment Number Date 
Final SAP 
 17 Nov 2020 
Confidentiality Statement 
Confidential 
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 2 of 39 
TABLE OF CONTENTS 
LIST OF ABBREVIATIONS .................................................................................................... 5 
1 
INTRODUCTION ............................................................................................................. 8 
2 
PROTOCOL SUMMARY ................................................................................................. 8 
2.1 
Study objectives ....................................................................................................... 8 
2.1.1 
Primary objective ........................................................................................... 8 
2.1.2 
Secondary objectives ..................................................................................... 9 
2.1.3 
Other/Exploratory objectives ......................................................................... 9 
2.2 
Study variables ......................................................................................................... 9 
2.2.1 
Pharmacokinetic variables ............................................................................. 9 
2.2.1.1 
Primary pharmacokinetic variables ...................................................... 9 
2.2.1.2 
Secondary pharmacokinetic variables .................................................. 9 
2.2.1.3 
Other/Exploratory pharmacokinetic variables ................................... 10 
2.2.2 
Safety variables ............................................................................................ 10 
2.2.2.1 
Secondary safety variables ................................................................. 10 
2.2.2.2 
Other/Exploratory safety variables .................................................... 10 
2.2.3 
Immunogenicity variable ............................................................................. 10 
2.2.3.1 
Other/Exploratory immunogenicity variable ..................................... 10 
2.3 
Study design and conduct ...................................................................................... 10 
2.4 
Determination of sample size ................................................................................. 11 
3 
DATA ANALYSIS CONSIDERATIONS ...................................................................... 12 
3.1 
General presentation of summaries and analyses .................................................. 12 
3.2 
General study level definitions .............................................................................. 13 
3.2.1 
Analysis time points ..................................................................................... 13 
3.2.2 
Study periods ............................................................................................... 14 
3.3 
Definition of Baseline values ................................................................................. 14 
3.4 
Protocol deviations................................................................................................. 14 
3.4.1 
Covid-19 related protocol deviation ............................................................ 15 
3.5 
Analysis sets........................................................................................................... 15 
3.5.1 
Enrolled Set .................................................................................................. 15 
3.5.2 
Randomized Set ........................................................................................... 15 
3.5.3 
Full Analysis Set .......................................................................................... 15 
3.5.4 
Pharmacokinetic Concentration Set ............................................................. 15 
3.5.5 
Pharmacokinetic Per-Protocol Set ............................................................... 15 
3.6 
Treatment assignment and treatment groups ......................................................... 15 
3.7 
Coding dictionaries ................................................................................................ 16 
3.8 
Changes to protocol-defined analyses ................................................................... 16 
4 
STATISTICAL/ANALYTICAL ISSUES ....................................................................... 16 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 3 of 39 
4.1 
Adjustments for covariates .................................................................................... 16 
4.2 
Handling of dropouts or missing data .................................................................... 16 
4.2.1 
Pharmacokinetic concentration data ............................................................ 16 
4.2.2 
Safety laboratory data .................................................................................. 17 
4.2.3 
Anti-drug antibody data ............................................................................... 17 
4.2.4 
Dates and times ............................................................................................ 17 
4.2.5 
Impact Of COVID 19 .................................................................................. 19 
4.3 
Handling of repeated and unscheduled measurements .......................................... 19 
4.4 
Interim analyses and data monitoring .................................................................... 20 
5 
STUDY POPULATION CHARACTERISTICS ............................................................. 20 
5.1 
Subject disposition ................................................................................................. 20 
5.2 
Protocol deviations................................................................................................. 21 
5.3 
Impact COVID-19 on study visits ......................................................................... 22 
6 
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................ 22 
6.1 
Demographics ........................................................................................................ 22 
6.2 
Other Baseline characteristics ................................................................................ 23 
6.3 
Medical history and concomitant diseases ............................................................. 23 
6.4 
Prior and concomitant medications ........................................................................ 23 
6.4.1 
Definitions of prior and concomitant medications ...................................... 23 
6.4.2 
Presentation of prior and concomitant medications data ............................. 24 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE ............................................... 24 
8 
EFFICACY ANALYSES ................................................................................................ 24 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS .......................................... 24 
9.1 
Pharmacokinetics ................................................................................................... 24 
9.1.1 
Descriptive analysis of Pharmacokinetics data ............................................ 24 
9.2 
Statistical analysis of bioequivalence .................................................................... 26 
9.2.1 
Primary analysis ........................................................................................... 26 
9.2.2 
Secondary analysis ....................................................................................... 26 
9.2.3 
Sensitivity analysis ...................................................................................... 27 
10 IMMUNOGECITY ANALYSIS ..................................................................................... 27 
10.1 
Anti-drug antibodies .............................................................................................. 27 
11 SAFETY ANALYSES ..................................................................................................... 29 
11.1 
Extent of exposure ................................................................................................. 29 
11.2 
Adverse events ....................................................................................................... 29 
11.3 
Clinical laboratory evaluations .............................................................................. 31 
11.3.1 
Potential drug-induced liver injury .............................................................. 33 
11.4 
Vital signs, physical findings, and other observations related to safety ................ 33 
11.4.1 
Vital signs .................................................................................................... 33 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 4 of 39 
11.4.2 
Electrocardiograms ...................................................................................... 34 
11.4.3 
Physical examinations .................................................................................. 34 
12 OTHER ANALYSES ...................................................................................................... 35 
13 REFERENCES ................................................................................................................ 36 
14 APPENDICES ................................................................................................................. 37 
15 AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN (SAP) (IF 
APPLICABLE) ................................................................................................................ 38 
15.1 
AMENDMENT 1................................................................................................... 38 
15.2 
AMENDMENT 2................................................................................................... 38 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE ..................................................... 39 
 
LIST OF TABLES 
Table 3‒1: Expected Baseline Visits ...................................................................................... 14 
Table 4-1: Calculation rules for duration (days) of AEs (applicable also to ADEs) ............. 18 
Table 11‒1: Clinical laboratory measurements ....................................................................... 31 
 
LIST OF FIGURES 
Figure 2‒1: Study Schematic ................................................................................................... 11 
 
 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 5 of 39 
LIST OF ABBREVIATIONS 
%AUCex 
percentage of the AUC extrapolated from Clast 
ACP 
above the cut point 
ADAb 
anti-drug antibody 
ADE 
adverse device effect 
AE 
adverse event 
AI 
auto-injector 
ALP 
alkaline phosphatase 
ALQ 
above the limit of quantification 
ALT 
alanine aminotransferase 
ANOVA  
analysis of variance 
aPTT 
activated partial thromboplastin time 
AST 
aspartate aminotransferase 
AUC 
area under the plasma concentration-time curve from time zero to 
infinity. 
%AUCex 
percentage of the AUC extrapolated from Clast 
AUC0-t 
area under the plasma concentration-time curve from time zero to last 
quantifiable concentration. 
BCP 
below the cut-point 
BE 
bioequivalence 
BLQ 
below the limit of quantification 
BMI 
body mass index 
BUN 
blood urea nitrogen 
CF 
correction factor 
CI 
confidence interval 
CL/F  
Apparent total body clearance will be calculated as dose/AUC 
Cmax 
maximum observed plasma drug concentration 
COVID-19 
coronavirus disease 2019 
CP 
confirmed positive 
CRO 
contract research organization 
CSR 
clinical study report 
CV% 
between subject variability 
DCP 
data cleaning plan 
DEM 
data evaluation meeting 
ECG 
electrocardiogram 
eCRF 
electronic Case Report Form 
EMA 
European Medicines Agency 
ES 
enrolled set 
EudraCT 
European Union Drug Regulating Authorities Clinical Trials 
FAS 
full analysis set 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 6 of 39 
FDA 
Food and Drug Administration 
FSH 
follicle stimulating hormone 
geoCV 
geometric coefficient of variation 
geoMean 
geometric mean 
GGT 
gamma glutamyl transferase 
HbA1c 
glycosylated hemoglobin 
HBc-Ab 
hepatitis B core antibody 
HBsAg 
hepatitis B surface antigen 
hCG 
human chorionic gonadotropin 
HCV- Ab 
hepatitis C virus antibody 
HDL 
high density lipoprotein 
HIV 
human immunodeficiency virus 
HIV1/2-Ab 
HIV1/2 antibody 
HIV1-Ag 
HIV1 antigen 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
IMP 
investigational medicinal product 
IPD 
important protocol deviation 
LDH 
lactate dehydrogenase 
LDL 
low density lipoprotein 
LLOQ 
lower limit of quantification 
max 
maximum 
MedDRA 
Medical Dictionary for Regulatory Activities 
min 
minimum 
n 
number of participants with available measurements 
NCP 
not confirmed positive 
PDILI 
potential drug-induced liver injury 
PK 
pharmacokinetic 
PKCS 
Pharmacokinetic Concentration Set 
PK-PPS 
pharmacokinetic per protocol set 
PT 
preferred term 
QTcF 
QT corrected for heart rate using Fridericia’s formula 
RBC 
red blood cell 
RS 
randomized set 
RT-PCR 
real-time reverse transcriptase polymerase chain reaction 
SADE 
serious adverse device effect 
SAE 
serious adverse event 
SAP 
statistical analysis plan 
SARS-CoV-2 
severe acute respiratory syndrome coronavirus 2 
sc 
subcutaneous 
SD 
standard deviation 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 7 of 39 
SFU 
safety follow-up 
SOC 
system organ class 
SS 
safety syringe 
t½ 
apparent terminal half-life 
TEAE 
treatment-emergent adverse event 
TFL 
tables, figures and listings 
tmax 
time of occurrence of Cmax 
TMF 
trial master file 
ULN 
upper limit of normal 
Vz/F 
Apparent volume of distribution will be calculated as CL/λz 
WBC 
white blood cell 
WHO-DD 
World Health Organization Drug Dictionary 
λz 
apparent terminal elimination rate constant 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 8 of 39 
1 
INTRODUCTION 
Bimekizumab 320mg is currently administered as 2x1mL subcutaneous (sc) injections of 160mg 
(the dose being assessed in the Phase 3 psoriasis studies). To provide additional options to 
healthcare professionals and patients, it is considered of benefit (by UCB) to develop 320mg 
bimekizumab device presentations (i.e., secondary functional packaging) where the dose can be 
delivered as a single 2mL sc injection. Study UP0068 aims to compare the pharmacokinetics 
(PK) of bimekizumab 320mg when administered sc using a 2mL safety syringe (SS; 
bimekizumab-SS-2mL, test 1) versus 2x1mL safety syringe (bimekizumab-SS-2x1mL, reference 
1) or when administered sc using a 2mL auto-injector (AI; bimekizumab-AI-2mL, test 2) versus 
2x1mL auto-injector (bimekizumab-AI-2x1mL, reference 2) to support the development of the 
2mL SS and AI presentations. 
The purpose of this statistical analysis plan (SAP) is to provide all necessary information to 
perform the required statistical analyses of study UP0068. It also defines the summary Tables, 
Figures and listings (TFLs) to be included in the final Clinical Study Report (CSR) according to 
the study protocol. 
This SAP is based on, and assumes familiarity with the original study protocol amendment 1, 
dated 24 Jul 2020. 
Unless specified in the sections below, the study will be analyzed as described in the most recent 
version of the protocol. If a future protocol amendment necessitates a substantial change to the 
statistical analysis of the study data, this SAP will be amended accordingly. In addition, if the 
analysis definitions are modified or updated prior to database lock, a SAP amendment will be 
required. If, after database lock, additional analyses are required to supplement the planned 
analyses described in this SAP, these changes will be described in the CSR together with the 
associated rationale. 
The content of this SAP is compatible with: 
• The International Council for Harmonization (ICH) and E9 Guidance documents1 
• Food and Drug Administration (FDA) guidance2 
• European Medicines Agency (EMA) guidelines3,4  
• Canada Health ministry guidance5,6  
UCB is the Sponsor and PAREXEL is the Contract Research Organization (CRO) for this study. 
2 
PROTOCOL SUMMARY 
2.1 
Study objectives 
2.1.1 
Primary objective 
The primary objective of the study is: 
• To compare the PK of bimekizumab 320mg when administered sc using the bimekizumab-
SS-2mL presentation (test 1) versus the bimekizumab-SS-2x1mL presentation (reference 1) 
or the bimekizumab-AI-2mL presentation (test 2) versus the bimekizumab-AI-2x1mL 
presentation (reference 2) in healthy study participants 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 9 of 39 
2.1.2 
Secondary objectives 
The secondary objectives of the study are: 
• To assess safety and tolerability of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-2x1mL, bimekizumab-SS-2mL, bimekizumab-AI-
2x1mL or bimekizumab-AI-2mL presentation in healthy study participants 
• To assess additional PK parameters of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-2x1mL, bimekizumab-SS-2mL, bimekizumab-AI-
2x1mL or bimekizumab-AI-2mL presentation in healthy study participants 
2.1.3 
Other/Exploratory objectives 
The other/exploratory objectives of the study are: 
• To assess additional PK parameters of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-2x1mL, bimekizumab-SS-2mL, bimekizumab-AI-
2x1mL or bimekizumab-AI-2mL presentation in healthy study participants 
• To assess immunogenicity of a single sc dose of bimekizumab 320mg when administered 
using the bimekizumab-SS-2x1mL, bimekizumab-SS-2mL, bimekizumab-AI-2x1mL or 
bimekizumab-AI-2mL presentation in healthy study participants 
• To assess additional safety and tolerability of a single sc dose of bimekizumab 320mg when 
administered using the bimekizumab-SS-2x1mL, bimekizumab-SS-2mL, bimekizumab-AI-
2x1mL or bimekizumab-AI-2mL presentation in healthy study participants 
2.2 
Study variables 
2.2.1 
Pharmacokinetic variables 
The PK parameters provided in this section will be derived from the plasma concentration data. 
2.2.1.1 
Primary pharmacokinetic variables 
The primary PK parameters are: 
• AUC: Area under the plasma concentration-time curve from time zero to infinity, calculated 
as calculated as AUC=AUCt+Clast/λz, where Clast is the last observed quantifiable plasma 
drug concentration and λz is the apparent terminal elimination rate constant 
• AUC(0-t): Area under the plasma concentration-time curve from time zero to the last 
quantifiable concentration, as determined using the linear trapezoidal rule 
• Cmax: Maximum observed plasma drug concentration 
2.2.1.2 
Secondary pharmacokinetic variables 
The secondary PK parameters are: 
• t½: Apparent terminal half-life, reported in units of days, as determined via simple linear 
regression (slope=-λz) of natural log (ln) concentration vs time for data points in the terminal 
phase of the concentration-time curve. t½ is calculated as ln2/λz 
• tmax: Time to occurrence of Cmax 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 10 of 39 
2.2.1.3 
Other/Exploratory pharmacokinetic variables  
The other/exploratory PK parameters are: 
• %AUCex: Percentage of the AUC extrapolated from Clast 
• CL/F: Apparent total body clearance after sc administration, calculated as Dose/AUC 
• Vz/F: Apparent volume of distribution, calculated as CL/λz 
2.2.2 
Safety variables 
2.2.2.1 
Secondary safety variables 
The secondary safety and tolerability endpoints are: 
• Treatment emergent adverse events (TEAEs) 
• Treatment emergent serious adverse events (SAEs) 
2.2.2.2 
Other/Exploratory safety variables 
The other/exploratory safety and tolerability endpoints are: 
• Vital signs (pulse rate, blood pressure, and tympanic body temperature) 
• Safety laboratory data (hematology [including coagulation/hemostasis tests], clinical 
chemistry, and urinalysis) 
• 12-lead electrocardiogram (ECG) assessments 
2.2.3 
Immunogenicity variable 
2.2.3.1 
Other/Exploratory immunogenicity variable 
The other/exploratory immunogenicity endpoint is: 
• Incidence of bimekizumab antidrug antibodies (ADAbs) 
2.3 
Study design and conduct 
This is a Phase 1, open-label, single-center, randomized, parallel-group, single-dose, 4-arm 
bioequivalence (BE) study to compare the PK of bimekizumab 320mg when administered as 
either a 1x2mL or 2x1mL sc injection in healthy male and female study participants. The SS and 
AI device presentations will be assessed. The 4 arms will be: 
1. bimekizumab-SS-2mL (test 1) 
2. bimekizumab-SS-2x1mL (reference 1) 
3. bimekizumab-AI-2mL (test 2) 
4. bimekizumab-AI-2x1mL (reference 2) 
Two independent comparisons will be made: test 1 versus reference 1 and test 2 versus  
reference 2. 
Four hundred healthy male and female study participants will participate in the study 
(approximately 100 study participants in each of 4 arms). Each study participant will receive a 
single-dose administration of bimekizumab 320mg. The duration of the study will be 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 11 of 39 
approximately 168 days, including 27 days of Screening, admission on Day -1, an inhouse 
Treatment Period from Day 1 to Day 3, Outpatients Visits until Day 112, and a Safety Follow-
Up (SFU) Visit on Day 140. Randomization will occur on Day 1 prior to dosing. The schematic 
diagram of the study is presented in Figure 2‒1. 
Figure 2‒1: Study Schematic 
 
 
AI=auto-injector; SS=safety syringe 
The study design is deemed appropriate for conduct in healthy study participants during the 
COVID-19 pandemic. 
2.4 
Determination of sample size 
This is a formal BE study to compare the PK of bimekizumab-SS-2mL (test 1) versus 
bimekizumab-SS-2x1mL (reference 1), and bimekizumab-AI-2mL (test 2) versus bimekizumab-
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 12 of 39 
AI-2x1mL (reference 2). Two independent comparisons will be made (i.e., test 1 versus 
reference 1 and test 2 versus reference 2). 
The between subject variability (CV%) observed in previous small studies following a single 
dose administration of bimekizumab in healthy study participants (i.e., UP0031, RA0124, 
UP0033, and UP0074) was 21% to 25% for AUC and 23% to 33% for Cmax. 
Assuming a geometric mean ratio of 0.9 between each pair of formulations and a between 
subject variability (CV%) of 33%, 93 study participants per group are required to assess BE 
(using an acceptance range of 0.8 to 1.25) with 80% power at the 5% significance level. If the 
true mean ratio between each pair of formulations is 0.95, then with the same assumptions on 
variability and significance level there is >95% power to determine BE for that pair of 
formulations. 
Sample size estimation was performed using SAS software (version 9.4). 
Assuming a dropout rate and non-evaluable study participants of approximately 10%, 100 study 
participants per group for a total of 400 study participants are to be enrolled in the study. If this 
10% rate is likely to be exceeded, due to unforeseen circumstances during the COVID-19 
pandemic, then participants may be replaced. 
 
3 
DATA ANALYSIS CONSIDERATIONS 
3.1 
General presentation of summaries and analyses 
Statistical analysis and generation of tables, figures, participant data listings, and statistical 
output will be performed using Statistical Analysis System® (SAS®) version 9.4 or later (SAS 
Institute, Cary, NC, USA). All tables and listings will use Courier New font size 9. 
Descriptive statistics will be displayed to provide an overview of the study results. For 
continuous variables, descriptive statistics will include number of participants with available 
measurements (n), mean, standard deviation (SD), median, minimum (min), and maximum 
(max). 
For categorical variables, the number and percentage of participants in each category will be 
presented. Unless otherwise noted, the denominator for percentages should be based on the 
number of participants included in the respective analysis set. For simple summaries, participants 
with missing data can generally be accounted for using either of the following approaches: 
• For summaries of demographics and Baseline characteristics: summarize percentages based 
on all participants in the analysis set and include a “Missing” category (corresponding to 
participants with missing data at the time of the variable being summarized) as the last row in 
the list of categories being summarized. 
• For summaries of safety endpoints, unless otherwise specified: summarize percentages based 
only on those participants with observed data for the variable being summarized. As the 
denominator may be different from the number of participants in the analysis set being 
considered, the denominator should be displayed in the table. The general format for 
displaying this will be “n/Nsub (%)”. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 13 of 39 
Percentages will be presented to 1 decimal place. If the percentage is 100%, do not present a 
decimal. If the percentage is 0, do not present the percentage. Typically, the % sign should be 
presented in the column header, but not with each individual value. 
For PK parameters other than tmax, summary statistics will include geometric mean (geoMean), 
geometric coefficient of variation (geoCV), 95% confidence intervals (CIs) for the geoMean, 
arithmetic mean, SD, median, min and max. 
For tmax, summary statistics will include median, min and max. 
All summaries of PK variables will be based on the observed values. No imputation will be used. 
Whenever the same data are reported both locally and via the central laboratory, analysis will be 
based on centrally analyzed data. 
Decimal places for descriptive statistics will always apply the following rules: 
• “n” will be an integer 
• Mean, SD, and median will use one additional decimal place compared to the original data 
• CV [%] will be presented with one decimal place 
• Min and max will have the same number of decimal places as the original value 
Derived variables in general will display the mean, SD and median to 1 more decimal place than 
the variables used in the derivation. If the number of decimal places reported in the raw data is 
varied then use either the maximum raw number of reported decimal places or 3, whichever is 
the lowest, as a guide for the descriptive statistics. 
If participants have more than one observation for a given time point, the observation closest to 
the intended time point will be used. If both observations are equidistant from the intended time 
point, then the later value will be used. 
Data listings containing all documented data and all derived data will be generated. 
3.2 
General study level definitions 
3.2.1 
Analysis time points 
Relative day for an event will be derived with the date of the sc injection of study drug as 
reference. 
Relative days for an event or measurement occurring before the date of the sc injection of study 
drug are calculated as follows: 
 
Relative Day = [(Event Date – Date of sc injection)] 
 
 
 
 
 
 
 
 
 
[1] 
The relative day for an event or measurement occurring on or after the reference date to the date 
of the sc injection is calculated as follows: 
 
Relative Day = [(Event Date – Date of sc injection) + 1] 
 
 
 
 
 
 
 
 
[2] 
There is no relative Day 0. Relative day is not calculated for partial dates in cases where relative 
day is shown in a participant data listing. In such cases, relative day should be presented as ‘- -’ 
in the participant data listings. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 14 of 39 
3.2.2 
Study periods 
The duration of the study for a study participant will be approximately 168 days; consisting of 
the following periods:  
• Screening Period (Day -28 to Day -2) 
• Inhouse Treatment Period (Day -1 to Day 3). Subjects will be dosed on Day 1. 
• Outpatient Period (Day 4 to Day 112) 
• Safety follow-up (Day 140) 
A study participant is considered to have completed the study if he/she has completed all phases 
of the study including the Day 140 SFU Visit or the last scheduled procedure. 
3.3 
Definition of Baseline values 
Baseline will be the last assessment prior to the sc injection of study drug, or if missing, the 
Screening value. Scheduled or unscheduled measurements can be used as the Baseline value. 
Expected measurement-specific Baseline time points are presented in Table 3‒1. If an 
unscheduled measurement occurs after the planned baseline measurement time point but before 
injection, then the unscheduled measurement will be used. 
Table 3‒1: 
Expected Baseline Visits 
Measurement 
Definition of Baseline 
Vital signs 
Day 1, Pre-dose value or, if missing, Day -1 value 
or, if both are missing, the screening value. 
Body weight 
Day -1 value or, if missing, the screening value. 
Single 12-lead ECG 
Day 1, Pre-dose value or, if missing, Day -1 value 
or, if both are missing, the screening value. 
Hematology (including coagulation/hemostasis) 
Day -1 value or, if missing, the screening value. 
Clinical Chemistry 
Day -1 value or, if missing, the screening value. 
Urinalysis 
Day -1 value or, if missing, the screening value. 
ADAb status 
Day 1 Pre-dose value 
ADAb=anti-drug antibody; ECG=electrocardiogram 
3.4 
Protocol deviations 
Important protocol deviations (IPDs) are identified as part of the data cleaning process in the 
Data Cleaning Plan (DCP). The objective of the data cleaning meeting will be to review and 
update (if necessary) the important protocol deviations in the DCP and discuss exclusion of study 
participants from analysis populations. 
Furthermore, overall trends in protocol deviations will be discussed at the Data Evaluation 
Meetings (DEMs). Through this data cleaning and evaluation process, all decisions regarding 
important protocol deviations and exclusions from analysis populations will be made. Protocol 
deviations (eg, missing assessments or visits) related to COVID-19 will be listed separately. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 15 of 39 
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the trial master file (TMF). 
After resolution of all issues, and documentation of all decisions, the database will be locked. 
3.4.1 
Covid-19 related protocol deviation 
UCB guidance on deviations and amendments related to SARS-CoV2 pandemic states that the 
identified COVID-19 related PDs need to be reviewed on an ongoing basis in case they 
collectively or individually may give reason to consider a protocol amendment (for example 
study design changes or changes to primary analysis methods etc). To facilitate this ongoing 
review, IPDs will be categorized as related to COVID-19 within the Clinical Trial Management 
System(CTMS). The COVID-19 related IPDs will be listed separately for consideration at the 
DEM. 
3.5 
Analysis sets 
3.5.1 
Enrolled Set 
The Enrolled Set (ES) will consist of all study participants who signed the informed consent 
form (ICF). 
3.5.2 
Randomized Set 
The Randomized Set (RS) will consist of all randomized study participants. 
3.5.3 
Full Analysis Set 
The Full Analysis Set (FAS) will consist of all randomized study participants who received full 
or partial Investigational Medicinal Product (IMP) according to the treatment the study 
participants actually received. The FAS will be used for summaries of demographics, medical 
history, prior and concomitant medications, IMP exposure, and general safety outcomes such as 
adverse events (AEs), laboratory parameters, vital signs, and ECGs. 
3.5.4 
Pharmacokinetic Concentration Set 
The PK Concentration Set (PKCS) will be a subset of the FAS, consisting of those study 
participants that received at least 1 dose of IMP and have at least 1 reported plasma 
concentration. All participants in the PKCS will be included in the listings. Participants with no 
protocol deviations to impact observed concentrations will be included in summary tables and 
figures of concentration-time profiles. 
3.5.5 
Pharmacokinetic Per-Protocol Set 
The PK Per-Protocol Set (PK-PPS) will be a subset of the FAS, consisting of those study 
participants who had no important protocol deviations affecting the PK variables and for whom a 
sufficient number of samples are available to determine at least 1 PK parameter. This analysis set 
will be used for all summaries and analyses of the PK parameters. 
3.6 
Treatment assignment and treatment groups 
Treatment assignment for the FAS and PK-PPS will be according to the actual treatment 
received. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 16 of 39 
Listings and summaries will be presented by treatment group and overall where applicable. The 
following order will be used in the TFLs: 
• Bimekizumab-SS-2mL: Single dose sc injection, bimekizumab 1x320mg, device presentation 
2mL SS 
• Bimekizumab-SS-2x1mL: Single dose sc injection, bimekizumab 2x160mg, device 
presentation 1mL SS   
• Bimekizumab-AI-2mL: Single dose sc injection, bimekizumab 1x320mg, device presentation 
2mL AI 
• Bimekizumab-AI-2x1mL: Single dose sc injection, bimekizumab 2x160mg, device 
presentation 1mL AI  
• All study participants 
For analysis conducted using the ES, an additional group for participants not randomized may be 
displayed, as applicable. 
3.7 
Coding dictionaries 
All AEs and medical history will be coded for analysis according to the Medical Dictionary for 
Regulatory Activities (MedDRA® 19.0) coding dictionary, using the latest MedDRA version 
available. Prior and concomitant medications will be coded for analysis using the latest version 
of the World Health Organization Drug dictionary (WHO-DD Sep 2015). Medical procedures 
will not be coded. 
3.8 
Changes to protocol-defined analyses 
None. 
4 
STATISTICAL/ANALYTICAL ISSUES 
4.1 
Adjustments for covariates 
There are no planned analyses including adjustments for covariates. 
4.2 
Handling of dropouts or missing data 
In general, there will be no imputation of missing data unless stated otherwise below. 
4.2.1 
Pharmacokinetic concentration data 
Measurements that are BLQ will be imputed with half of the LLOQ for the purpose of 
calculating the geoMean and its 95% CI, the geoCV, the arithmetic mean, and SD for summaries 
and figures. If any summary value (geoMean, arithmetic mean, lower CI level or minimum) is 
lower than LLOQ, then ‘BLQ’ will be displayed.  
For the individual figures, any concentrations that are BLQ will be regarded as missing, with the 
exception of pre-dose measurements BLQ on Day 1, which will be imputed with zero for linear 
scale plots. 
Additional rules for PK data summaries are provided in Section 9.1.1. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 17 of 39 
Pharmacokinetic concentration data will not be available to the study team until after the last 
scheduled procedure for the last study participant in the study, so the decision to replace 
participants who dropped out or are missing PK visits due to COVID-19 can be made in an 
unbiased manner.  
4.2.2 
Safety laboratory data 
Measurements below the limit of quantification (BLQ) will be imputed with half of the lower 
limit of quantification (LLOQ) for the purpose of calculating change and percentage change 
from Baseline for summaries and figures. Measurements above the limit of quantification 
(ALQ), if applicable, will be imputed to the upper limit of quantification. 
Descriptive statistics will be calculated if at most 33% of the individual data points at a time 
point are missing or are either not quantifiable (<LLOQ) or ALQ. If no participants have data at 
a given time point, then only n=0 will be presented. If n<3, then only the n, minimum and 
maximum will be presented. If n=3, then only n, minimum, median and maximum will be 
presented. The other descriptive statistics will be left blank. 
4.2.3 
Anti-drug antibody data 
Levels of ADAb that are BLQ will be regarded as missing for all individual ADAb figures. 
4.2.4 
Dates and times 
Partial dates/times may be imputed for the following reasons: 
• Classification of AEs as treatment-emergent 
• Classification of medications as prior or concomitant 
Imputed dates/times will not be shown in the listings; all dates will be displayed as reported in 
the database. 
The following rules will be applied for partial start dates/times: 
• If only the start month and year are specified, and these are not the same as the month and 
year of dosing then use the 1st of the month, or the date of Screening if this is later (if the 
latter imputation results in an end date that is earlier than the start date, then use the 1st of the 
month). If time is missing this will be imputed as 00:00 h; 
• If only the start month and year are specified, and the month and year of dosing are the same 
as the month and year of the start date, then use the date of dosing. If this results in an 
imputed start date that is after the specified end date, then use the 1st of the start month, or 
the date of Screening if this is later (if the latter imputation results in an end date that is 
earlier than the start date, then use the 1st of the month). If the imputed date is the date of 
dosing then time will be imputed as the start time of the sc injection (i.e., event will be 
regarded as treatment-emergent); 
• If only the year is specified, and the year of dosing is not the same as the year of the start date 
then use January 01 of the year of the start date. If time is missing this will be imputed as 
00:00 h; 
• If only the year is specified, and the year of dosing is the same as the year of the start date, 
then use the date of dosing. If this results in an imputed start date that is after the specified 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 18 of 39 
end date, then use January 01 of the year of the start date, or the date of Screening if this is 
later (if the latter imputation results in an end date that is earlier than the start date, then use 
January 01). If the imputed date is the date of dosing then time will be imputed as the start 
time of the sc injection (i.e., event will be regarded as treatment-emergent); 
• If the start date is completely unknown, then use the date of dosing. If this results in an 
imputed start date that is after the specified end date, then use January 01 of the year of the 
end date, or the date of Screening if this is later (if the latter imputation results in an end date 
that is earlier than the start date, then use January 01). If the imputed date is the date of 
dosing then time will be imputed as the start time of the sc injection (i.e., event will be 
regarded as treatment-emergent). 
Any medication with a start date on the dosing date and time unknown, will be assumed to be 
concomitant. 
The following rules will be applied for partial stop dates: 
• If only the month and year are specified, then use the last day of the month; 
• If only the year is specified, then use December 31 of the known year; 
• If the stop date is completely unknown, do not impute the stop date. 
Missing or partially missing date and/or times will be imputed as described in Table 4-1 for the 
calculation of duration of each AE. Adverse event duration is computed and reported in day and 
time format: xx d hh:mm. 
Table 4-1: 
Calculation rules for duration (days) of AEs (applicable also to ADEs) 
Data 
Availability 
Onset 
Date/Time 
Outcome 
Date/Time 
Calculation Rules 
Complete data 
D1/T1 
D2/T2 
Duration = [(D2 – D1) *24 + (T2 – T1)]/24 d 
End time missing 
D1/T1 
D2/-- 
End time is substituted by time 23:59h (=23.98 in 
decimal format). 
Duration = < [(D2 – D1) *24 + (23.98 – T1)]/24 d 
Start time 
missing 
D1/-- 
D2/T2 
Onset time is substituted by 00:00h. 
Duration = < [(D2 – D1) *24 + T2]/24 d 
Start and end 
time missing 
D1/-- 
D2/-- 
Duration = < (D2 – D1) + 1 
Start day and 
time missing 
--/-- 
D2/T2 
Duration = < [(D2 – D0) *24 + (T2 – T0)] / 24 d 
For a participant in the FAS, D0 and T0 are the date 
and time of dosing and for screen failures, D0 = the 
Screening Visit date and T0 = 0. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 19 of 39 
Table 4-1: 
Calculation rules for duration (days) of AEs (applicable also to ADEs) 
Data 
Availability 
Onset 
Date/Time 
Outcome 
Date/Time 
Calculation Rules 
End day and 
time missing 
D1/T1 
--/-- 
For ongoing AE duration = > Discharge day – D1 d 
For resolved AE duration = < Discharge day – D1 d 
Where Discharge Day refers to the date of the SFU 
visit or date of discontinuation. 
For any AEs with known start date/time after the 
date of discontinuation, the date of last contact will 
be used as the discharge day. 
Start and end 
date missing 
 
--/-- 
--/-- 
For ongoing AE duration = > Discharge day – D0 d 
For resolved AE duration = < Discharge day – D0 d 
Where Discharge Day refers to the date of the 
Safety 
Follow-Up visit or date of discontinuation. 
For a participant in the FAS, D0 is the date of 
dosing and for screen failures, D0 = the screening 
visit date. 
ADE=Adverse Device Effect; AE = Adverse Event; FAS=Full Analysis Set 
4.2.5 
Impact Of COVID 19 
The FDA and EMA (see REFERENCES) have provided guidance to help assure the safety of 
study participants, maintaining compliance with good clinical practice (GCP), and minimizing 
risks to study integrity during the COVID-19 pandemic. At the time of writing, the impact of the 
pandemic is still evolving and regulators continue to clarify their position. One of the 
recommendations is a risk assessment of the impact of COVID-19 on study integrity and 
interpretability of potential study results. In particular, the major statistical principles that need to 
be consider when considering the impact of COVID-19 on studies and how to handle missing or 
delayed assessments resulting from the pandemic. The impact of the COVID-19 pandemic, at the 
visit level, will be assessed by data collected on a specific COVID-19 impact CRF. Drop outs 
due to COVID-19 will be handled in the same way as drop out for other reasons. Should one of 
the ongoing reviews of COVID-19 related PDs (see Section 3.4) suggest that the impact of 
COVID-19 is more significant than expected e.g. in the case of a second wave, the SAP may be 
updated to include details of strategies to handle missing data and/or sensitivity analyses. 
4.3 
Handling of repeated and unscheduled measurements 
All repeated and unscheduled measurements will be presented in the listings. Repeated and 
unscheduled measurements will not be used for statistical analysis or summary tables, unless the 
repeated measurement was performed due to unreliable values/technical reasons, or the repeated 
measurement occurred prior to IMP administration and is defined as the 'Baseline'. The 
following general rules will apply to all repeated and unscheduled measurements: 
• For repeated measurements obtained prior to the IMP administration, the latest reliable value 
(which may be scheduled or unscheduled) will be used in the calculation of descriptive 
statistics  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 20 of 39 
• For repeated measurements obtained at any time point after dosing, the first reliable value of 
any repeated measurements will be used in the calculation of changes from Baseline and for 
the descriptive statistics.  
4.4 
Interim analyses and data monitoring 
No formal interim analysis is planned for this study. 
Two DEMs will be performed for this study prior to the final analysis. The purpose of these 
DEM reviews will be to review all protocol deviations, define the analysis sets as defined in 
Section 3.5 and check the quality of the data. The reviews will also help decide how to manage 
problems in the participants’ data (e.g. missing values and withdrawals). 
Accepted deviations from planned time points will be described in the appropriate documents 
and included in the Study Master File. After the pre-analysis review, resolution of all issues, and 
documentation of all decisions (including inclusion into each of the analysis sets) at the final 
DEM, the database will be locked. 
5 
STUDY POPULATION CHARACTERISTICS 
5.1 
Subject disposition 
Participant screening and primary reason for screen failure will be summarized using the ES. The 
summary will include the following: 
• Number of participants screened 
• Number and proportion of participants rescreened 
• Number and proportion of participants with screen failures (Not counting successfully 
rescreened participants) 
• Number and proportion of screen failures by primary reason for screen failure (based on the 
later screening visit, in case of rescreen). 
Disposition of analysis sets will be summarized using the ES. The summary will include the total 
number of participants in the ES, as well as the number and percentage of participants in each 
analysis set by treatment group. The percentages will be calculated based on the RS. 
Study completion/discontinuation and primary reason for discontinuation will be summarized by 
treatment group and overall using the RS. The summary will include the following: 
• Number and percentage of participants that started the study  
• Number and percentage of participants completing the study 
• Number and percentage of participants discontinuing the study 
• Number and percentage of participants discontinuing the study by primary reason for 
discontinuation. 
Participants that started the study are defined as participants that were randomized. Participants 
completing the study are those participants completing the SFU visit, i.e., the participant will be 
regarded as a completer if the SFU (Day 140) visit was completed. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 21 of 39 
Study discontinuation due to AEs will be summarized using the RS. The summary will present 
the number and percentage of participants who discontinued the study due to AE of the by 
treatment group and overall. 
By-participant listings of participant disposition will be provided by treatment group using the 
ES, and will include the following: 
• Study termination/completion status 
• Date of informed consent 
• Date of randomization 
• Date and time of study medication administration 
• Date of last contact 
• Date of premature study termination for successfully screened participants dropping out of 
the study 
• Date of screen failure for screen failure participants (based on the later screening visit in case 
of rescreen) 
• Primary reason for premature study termination, as applicable 
• Primary reason for screen failure, as applicable (based on the later screening visit in case of 
rescreen). 
By-participant listings of study discontinuation will be presented by treatment group, using the 
RS. The listing will include the primary reason for discontinuation and the number of days since 
study medication administration. 
By-participant listings of visit dates will be presented by treatment group using the FAS. 
By-participant listings of participant who did not meet study eligibility criteria will be presented 
by treatment group, using the ES. The listing will include inclusion criteria that were not met and 
the exclusion criteria that were met. A glossary listing of inclusion and exclusion criteria will 
also be provided. 
By-participant listings of participant inclusion in each analysis set will be presented by treatment 
group, using the ES. 
5.2 
Protocol deviations 
IPDs will be identified and classified by the deviation types listed in the IPD specification 
document. 
IPDs will be summarized by treatment group and overall using the RS. The summary will 
include the following: 
• Number and percentage of participants with no IPDs 
• Number and percentage of participants with at least one IPD 
• Number and percentage of participants by type of protocol deviation 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 22 of 39 
By-participant listings of IPDs as identified in the DEMs will be provided by treatment group 
using the RS. This will include deviation type, deviation description, and whether the deviation 
led to exclusion from the PK-PPS. Similar listings and tables will be produced for IPDs related 
to COVID-19. 
5.3 
Impact COVID-19 on study visits 
A listing of visits impacted by COVID-19 will be presented for all participants based on the ES. 
This will include visit, visit date, relative day, impact category, relationship to COVID-19 and 
the narrative of the event. The number and percentage of participants with visits impacted by 
COVID-19 will be summarized for treatment group for relationship to COVID-19 and impact 
category by country. The denominator for the percentages will be the number of participants in 
the ES. 
6 
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS 
6.1 
Demographics 
Baseline demographic variables will be summarized by treatment group and overall using the 
FAS. 
The following continuous variables will be summarized using descriptive statistics: 
• Age (years), as recorded in the electronic Case Report Form (eCRF) (will not be derived) 
• Height (m) 
• Weight at screening (kg) (at Screening and at Admission [Day -1]) 
• Body Mass Index (BMI) (kg/m2) 
The BMI value collected in the eCRF will not be used for this summary. The BMI will be 
recalculated using the following formula and reported to 1 decimal place: 
𝐵𝑀𝐼 (𝑘𝑔/𝑚2) = 
Weight (kg)
(Height (m))2  
 
 
 
 
 
 
 
 
 
 
 
 
 
[3] 
The following categorical variables will be summarized using frequency counts and percentages: 
• For the EudraCT reporting, the age categories will include:  
− 18 - < 65 years 
− 65 - < 85 years 
− ≥ 85 years 
• For the clinicaltrials.gov reporting, the age categories will include:  
− ≤18 years 
− 19 to <65 years 
− ≥65 years 
• Sex 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 23 of 39 
• Race 
• Ethnicity 
By-participant listings of demographic data will be provided by treatment group using the ES. 
This will include year of birth, age (years), sex, race and ethnicity, height (m), weight at 
screening (kg), weight at admission (kg), and BMI (kg/m2). 
By-participant listings of childbearing potential information will be provided by treatment group 
using the ES. 
6.2 
Other Baseline characteristics 
Lifestyle will be summarized by treatment group and overall using the FAS. The following 
categorical variables will be summarized using frequency counts and percentages: 
• Alcohol use (Never, Current, Former) 
• Caffeinated beverages use (Never, Current, Former) 
• Tobacco use (Never, Current, Former). 
By-participant listings of lifestyle data will be provided by treatment group for the ES. In 
addition to the items presented above, the listing will include stop date of tobacco use (or 
ongoing, as applicable) and illicit drug use. 
6.3 
Medical history and concomitant diseases 
Previous and ongoing medical history conditions will be summarized by treatment group and 
overall using the FAS. The summary will include the following: 
• Number and percentage of participants with any previous and ongoing medical history 
conditions. 
• Number and percentage of participants with previous and ongoing medical history conditions 
by MedDRA system organ class (SOC) and preferred term (PT). 
By-participant listings of previous and ongoing medical history conditions will be provided by 
treatment group for the FAS. This will include MedDRA SOC and PT, reported condition, start 
date and stop date (or status ongoing, as applicable). 
By-participant listings of procedure history and concomitant medical procedures will be 
provided, by treatment group for the ES. This will include reported procedure term and 
procedure date. 
6.4 
Prior and concomitant medications 
6.4.1 
Definitions of prior and concomitant medications 
If a participant takes a medication before the date of study medication administration, this 
medication will be categorized as ‘prior medication’. With this definition, any medication 
recorded that has been taken for at least 1 day before the date of study medication administration 
will be considered as prior. This includes medications that started prior to study medication 
administration and continued after. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 24 of 39 
Medication not stopped before the date of study medication administration will be classified as 
‘concomitant medication’. Medication will also be labeled as ‘concomitant medication’ when the 
start date is between the date (including the date) of study medication administration and the date 
of the participant’s last study visit.  
From the definitions above, any medication that started prior to dosing and continued after 
dosing will be classified as both prior and concomitant. 
Any medications with missing dates and/or times will be handled as described in Section 4.2.4 in 
order to classify them as prior or concomitant. 
6.4.2 
Presentation of prior and concomitant medications data 
Prior and concomitant medications will be summarized by treatment group and overall using the 
FAS. The summary will include the following: 
• Number and percentage of participants with any prior medications. 
• Number and percentage of participants with prior medications by ATC class, presenting 
WHO-DD Anatomical Main Group (ATC Level 1), Pharmacological Subgroup (ATC Level 
3), and preferred term. 
• Number and percentage of participants with any concomitant medications. 
• Number and percentage of participants with concomitant medications by ATC class, 
presenting WHO-DD Anatomical Main Group (ATC Level 1), Pharmacological Subgroup 
(ATC Level 3), and preferred term. 
By-participant listings of prior and concomitant medications will be provided by treatment group 
for the FAS. This will include Anatomical Main Group, Pharmacological subgroup, preferred 
term, reported term, dose per intake and unit, frequency, formulation, route, indication, category 
(prior/concomitant/prior and concomitant), start date and end date (or ongoing, as applicable). 
7 
MEASUREMENTS OF TREATMENT COMPLIANCE 
As this is a single dose study and dosing is performed in-house by the investigator or member of 
staff, no specific assessment or compliance is warranted. Any dosing deviation will be addressed 
in the DEM and described in the CSR. 
8 
EFFICACY ANALYSES 
Efficacy is not evaluated in this study. 
9 
PHARMACOKINETICS AND PHARMACODYNAMICS  
9.1 
Pharmacokinetics 
Unless otherwise specified, all analysis described in this section will be performed on the PK-
PPS. 
9.1.1 
Descriptive analysis of Pharmacokinetics data 
Individual plasma concentrations of bimekizumab will be listed by treatment group for the FAS 
and will include the actual and nominal sampling times and the corresponding time deviations. 
The window allowance document will define the acceptable deviations at each timepoint; 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 25 of 39 
samples obtained outside this tolerance will be considered as protocol deviations. All protocol 
deviations will be discussed at the DEM and any exclusion from analysis will be documented 
accordingly (Section 3.4). 
Plasma concentrations of bimekizumab will be summarized by treatment group and nominal 
sampling time. This will include number of participants, arithmetic mean, median, SD, 
minimum, maximum, geometric mean and geometric CV and 95% CI for the geometric mean 
(assuming log-normally distributed data). 
Individual plasma concentration-time profiles of bimekizumab will be displayed graphically on 
linear and semi-logarithmic scale. In addition, combined individual (spaghetti) plots will be 
displayed by treatment group with all participants in a given treatment group overlaid on the 
same plot (linear and semi-logarithmic scale).  
Geometric mean profiles with lower and upper limits of the 95% CI for the linear scale and 
without confidence limits for the semilogarithmic scale will be displayed. The mean plots will be 
displayed on the same graph. 
All figures will include a reference line for the LLOQ on the semi-logarithmic panel. 
The following PK parameters (see definitions in Section 2.2.1) will be derived from the plasma 
concentrations of bimekizumab: 
• Primary PK parameters 
− AUC, AUC(0-t), Cmax 
• Secondary PK parameters 
− t½, tmax 
• Other/Exploratory PK parameters 
− %AUCex 
− CL/F 
− Vz/F 
For calculation of the PK variables, the actual sampling times will be used. 
All PK variables will be listed and summarized by treatment group for the PK-PPS including 
number of participants, arithmetic mean, median, SD, minimum, maximum, geometric mean, 
geoCV and 95% CI for the geometric mean. 
The following rules will apply for the PK data summaries: 
• Values below the LLOQ will be reported as BLQ for individual data and will be 
substituted with LLOQ/2 for the descriptive statistics 
• Descriptive statistics of PK concentrations will be calculated only if at least ⅔ of the 
individual data at a specific sampling timepoint are measured and are quantifiable (i.e., 
above LLOQ) and if n≥4. If n<3, then only n, minimum and maximum will be presented 
and if n=3, then only n, median, minimum and maximum will be presented and the other 
descriptive statistics will be left blank 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 26 of 39 
• Descriptive statistics of PK parameters will be calculated only if at least ⅔ of the 
individual data are calculable and if n≥4. If n<3, then only n, minimum and maximum 
will be presented and if n=3, then only n, median, minimum and maximum will be 
presented and the other descriptive statistics will be left blank. For tmax, only n, median, 
minimum and maximum will be presented 
• If no participant has data, only n=0 will be presented 
• The 95% lower and upper CI should be left blank if the SD (or equivalently the geoCV) 
is equal to 0 
• The geoCV will be calculated using the following formula where SD is the standard 
deviation of the log-transformed values: 
𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐 𝐶𝑉 (%) = √(exp(𝑆𝐷2) −1) x 100  
 
 
 
 
 
 
 
 
[3] 
9.2 
Statistical analysis of bioequivalence 
9.2.1 
Primary analysis 
The primary PK parameters (AUC, AUC(0-t) and Cmax) will be evaluated according to a univariate 
model of analysis of variance (ANOVA). The model will include treatment group as a fixed 
effect. The dependent variables will be logarithmically transformed by natural logarithms (ln) 
prior to analysis.  
Two independent comparisons will be made: 
• Test 1: Bimekizumab-SS-2mL versus Reference 1: Bimekizumab-SS-2x1mL 
• Test 2: Bimekizumab-AI-2mL versus Reference 2: Bimekizumab-AI-2x1mL 
For each comparison, the difference between the least squares means (LSM) will be estimated 
and back transformed in order to obtain the geometric mean ratio for the corresponding 
Test/Reference together with the 90% CI for the ratio. 
For each of the respective comparisons, BE will be concluded if the 90% CIs for the ratio of the 
respective comparison are fully included in the acceptance range from 0.8 to 1.25 for AUC, 
AUC(0-t) and Cmax. 
All participants in the PK-PPS will be included in the analysis as far as the data permit; a 
participant may be included in the analysis for one or more PK variables (i.e., if it was not 
possible to calculate AUC for a given participant, the participant may be included in the analysis 
of BE for AUC(0-t) and Cmax). 
The results of the BE analysis will be tabulated, for each comparison, including the geometric 
least squares means and 90% CI for treatment group, the estimated geometric mean ratio and 
90% CI for the corresponding Test/Reference as well as the CV%. 
9.2.2 
Secondary analysis 
A similar ANOVA, as described in Section 9.2.1, will be performed on log-transformed t½ to 
compare elimination characteristics between treatment groups (i.e., Test 1 versus Reference 1 
and Test 2 versus Reference 2). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 27 of 39 
The point estimate and the 90% CI for the median treatment differences for tmax will be 
computed according to the Hodges-Lehmann’s method. 
9.2.3 
Sensitivity analysis 
The following sensitivity analyses will be performed following the same model as described for 
the primary analysis (Section 9.2.1): 
1. Based on all nonpositive ADAb participants (Defined as any positive ADAb observed post 
baseline) 
2. Including body weight at Day -1 as covariate 
3. Corrected for measured protein content: 
For compliance with Canadian Health ministry guidance, AUC and Cmax ratio estimates and 90% 
CIs will be also presented as corrected for measured protein content (potency). A correction 
factor (CF) will be obtained as the ln-transformed ratio of the percent protein content 
(Reference/Test). Then, this factor will be added to the difference in LSMs to obtain, by 
exponentiation, the corrected AUC and Cmax geometric mean ratios and its 90 % CIs. 
For a given Reference/Test, the correction factor will be calculated using the below formula: 
𝐶𝐹= 100 × exp(
% 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒
% 𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 𝑇𝑒𝑠𝑡
)                     [4] 
The corrected ratio estimate for the PK parameter (AUC or Cmax) is calculated using the below 
formula: 
𝑅𝑎𝑡𝑖𝑜= 100 × exp(𝐿𝑆𝑀 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒+ 𝐶𝐹)                   [5] 
Where,  
𝐿𝑆𝑀 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒= 𝐿𝑆𝑀(𝑇𝑒𝑠𝑡) −𝐿𝑆𝑀(𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒)     [6] 
The corrected 90% CI for the ratio is obtained using the below formula: 
90% 𝐶𝐼= 100 × exp[(𝐿𝑆𝑀 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒+ 𝐶𝐹) ± 𝑡0.05,𝑛× 𝑠𝑒(𝐿𝑆𝑀 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒)]   [7] 
10 
IMMUNOGECITY ANALYSIS 
10.1 
Anti-drug antibodies 
ADAb will be measured using a 3-tiered assay approach: screening assay, confirmatory assay 
and titration assay. 
A screening cut point will be determined by the bioanalytical laboratory that will be used to 
determine the status of ADAb as above the cut point (ACP) or below the cut point (BCP). 
Samples presenting ADAb levels ACP are considered “potentially ADAb positive” and will be 
further evaluated in the confirmatory assay, the result of which will be reported as either 
“confirmed positive” (CP) or “not confirmed positive” (NCP). Confirmed positive samples 
(reported as CP) will be titrated, and the titer (reciprocal dilution factor including minimum 
required dilution) reported.  
ADAb status at any time point: 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 28 of 39 
• An ADAb status of positive (ADAb+) will be concluded for any participant with an ADAb 
level that is ACP and CP; 
• An ADAb status of negative (ADAb-) will be concluded for any participant with an ADAb 
level that is either BCP or ACP and NCP; 
Participant Classification: 
• A participant will be classified as having ADAb positivity at Baseline if the Day 1, pre-dose 
result is ADAb+; 
• A participant will be classified as overall positive if at least one post-Baseline measurement 
is ADAb+ (see definition above) (this includes participants who have negative and positive 
results at baseline); 
• A participant will be classified as overall negative if at all post-Baseline visits the ADAb 
status is negative (this includes participants who have positive and negative results at 
Baseline); 
• A participant will be classified as having treatment-emergent ADAb positivity when meeting 
one of the following criteria: 
− The Baseline result is ADAb-, and at least one post-Baseline time point is ADAb+; 
− The Baseline result is ADAb+, and at least one post-Baseline measurement shows a pre-
defined fold increase in titer or units/mL (as applicable) from the Baseline value (the fold 
increase from Baseline required to meet these criteria will be defined with the 
development of the assay and will be included in the TFLs). 
Analysis: 
Immunogenicity will be assessed through summary tables and figures and listing of individual 
results by participant. All analyses will be run on the FAS, unless specified otherwise. For all 
tabulations, percentages will be calculated based on the number of participants with non-missing 
data. 
• All individual participant-level ADAb results will be listed by treatment group. This will 
include the screening assay, confirmatory assay, and titer (if applicable). 
• Number and percentage of participants with a positive and negative ADAb status will be 
summarized at the time of each visit and overall, separated by treatment group and for all 
bimekizumab treated participants. 
• In addition, the first occurrence of treatment-induced ADAb positivity (based on the 
definitions above) will be summarized (number and percentage of participants) at each post-
Baseline visit, based on the PK-PPS. This tabulation will present the number and percentage 
of participants at each post-Baseline visit who fulfill at least one of the above defined criteria 
for treatment-emergent positivity; participants will be counted in the numerator based on the 
earliest visit at which one of these criteria is fulfilled. At other visits, participants will be 
counted in the denominator (assuming a measurement is available). For all tabulations, 
percentages will be based on the number of observations at each visit. This summary will 
exclude any samples with bimekizumab concentrations confirmed to be above the drug 
tolerance. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 29 of 39 
A separate listing will be presented showing the bimekizumab concentrations and ADAb 
measurements in the same output in adjacent columns, based on the PK-PPS. The listing will 
include the bimekizumab concentration, ADAb status (positive or negative) and screening assay 
results (ACP or BCP) and confirmatory assay results if applicable (NCP or CP), together with 
the titer if applicable. In addition, the time since the administration of study medication will be 
reported (in days). ADAb samples that are negative but have drug concentration above the drug 
tolerance characteristics of the assay will be flagged. 
Finally, individual participant plots will be presented displaying the ADAb titer and 
bimekizumab concentrations overlaid on the same figure for the FAS. The ADAb data will be 
plotted using a semi-logarithmic scale. ADAb samples that are negative but have drug 
concentration above the drug tolerance characteristics of the assay will be flagged on the plot. 
The rules for handling values that are BLQ in the bimekizumab concentration data are described 
Section 4.2.1.  For the ADAb data, any negative results for which there are no titers or units/mL 
(as applicable) available at a specific visit will be substituted with 0.001 for the purpose of the 
figure. 
11 
SAFETY ANALYSES 
Unless otherwise stated, all safety analyses will be presented for the FAS. 
11.1 
Extent of exposure 
All IMP administration details (including date/time of administration), injection site (left thigh or 
right thigh), duration of injection (seconds) and comments reported during the administration 
with the medical device will be listed using the FAS. In addition, a listing of batch and devices 
numbers used will be created using the FAS. 
11.2 
Adverse events 
Adverse events will be recorded from the time of informed consent until study completion. All 
AEs will be coded (Section 3.7) and categorized by relationship to bimekizumab. 
The following definitions will be used in the analysis of AEs: 
• A TEAE is defined as any event not present prior to the administration of IMP or any 
unresolved event already present before administration of IMP that worsens in intensity 
following exposure to study treatment 
• An ADE is defined as any AE related to the use of an investigational medicinal device i.e., 
where the causality to the device constituent is assessed as ‘related’ by the Investigator 
• A serious ADE (SADE) is an ADE that results in any of the consequences defined for a SAE, 
i.e., where the causality to the device constituent is assessed as ‘related’ by the Investigator 
and the AE is considered as SAE 
• An AE of special interest is any AE that a regulatory authority has mandated be reported on 
an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to 
the administration of a UCB product/compound. Potential Hy’s Law, defined as ≥3xULN 
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) with coexisting 
≥2xULN total bilirubin in the absence of ≥2xULN alkaline phosphatase (ALP), confirmed by 
repeat measurement, with no alternative explanation for the biochemical abnormality, must 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 30 of 39 
ALWAYS be reported to UCB as an AE of special interest (i.e., without waiting for any 
additional etiologic investigations to have been concluded). 
By definition, all ADEs and SADEs are also classified as TEAEs. 
The number and percentage of participants who experience TEAEs will be summarized by 
treatment group, SOC, and PT, based on the FAS (unless otherwise stated). 
If it is not possible (due to partial dates) to determine whether an AE is treatment emergent or 
not, it will be assumed to be a TEAE (Section 4.2.4). 
An overview of the occurrence and incidence of TEAEs will be provided by treatment group and 
overall. The overview will present individual occurrences as well as number and percentage of 
(unique) participants experiencing each of the following: 
• TEAEs 
• Serious TEAEs 
• Discontinuation due to TEAEs 
• Drug related TEAEs 
• Severe TEAEs 
• All Deaths (AEs leading to death) 
• Deaths (TEAEs leading to death) 
• ADEs 
• SADEs. 
Summaries of the occurrence and incidence of TEAEs and SAEs will be provided by treatment 
group and overall. The summary will present individual occurrences as well as number and 
percentage of (unique) participants, by MedDRA SOC and PT. These summaries will be 
provided for the following: 
• Incidence of TEAEs 
• Incidence of serious TEAEs 
• Incidence of TEAEs by maximum causal relationship with IMP 
• Incidence of TEAEs by maximum intensity 
• Incidence of serious TEAEs by maximum causal relationship with IMP 
• Incidence of fatal TEAEs by causal relationship with IMP 
• Incidence of non-serious TEAEs above threshold of 5% of participants 
In summaries including intensity, the following intensity categories will be summarized: ‘Mild’, 
‘Moderate’, ‘Severe’. Participants who experience the same event multiple times will be 
included in the most severe category for tabulations by maximum intensity. Events with missing 
intensity will be considered as ‘Severe’ events for summary purposes but recorded as missing in 
the listings. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 31 of 39 
In summaries including causal relationship to IMP, the following relationships will be 
summarized: ‘Not related’, ‘Related’. Participants who experience the same event multiple times 
will be included in the most related category for tabulations by maximum relationship. Events 
with missing causal relationship to IMP will be considered as ‘Related’ for the tabulations but 
presented as missing in the listings. 
For the summary of non-serious TEAEs above threshold of 5% of participants, only TEAEs 
which are reported in 5% of participants within a treatment group will be included. 
Adverse event summaries will be ordered by alphabetical SOC and decreasing frequency of PT 
within SOC in the overall column for tables including event counts. For tables including only 
number and percentage of participants, summaries will be ordered by alphabetical SOC and 
decreasing incidence of PT within SOC in the overall column. 
A listing will be presented by treatment group and participant for all AEs. This will include the 
onset date/time and outcome date/time of the event (including relative days), the AE duration, 
pattern of event, intensity, relationship, action taken and outcome. In addition, the listing will 
flag TEAEs, hospitalization, SAEs, ADEs and AE of special interest. Confirmed and suspected 
cases of SARS-CoV-2 infection will be recorded as AEs (or SAE, as required). 
11.3 
Clinical laboratory evaluations 
Laboratory variables will be grouped according to the laboratory function panel (Table 11‒1) 
and categorized as normal, high or low, if applicable, based on the reference range supplied by 
the analytical laboratory. 
Table 11‒1: Clinical laboratory measurements 
Category 
Panel 
Variable 
Serology 
Serology 
HbsAg, HBc-Ab (both IgG and IgM), 
HCV-Ab, HIV1-Ab, HIV1-Ag, HIV-2 
Ab 
Hematology 
Red blood cell 
Hemoglobina, hematocrit, RBCa 
Platelet 
Platelet counta 
White blood cell 
WBC counta 
White blood cell differential 
Absolute counts: ANCa, basophils, 
eosinophils, ALC, monocytes 
Percentages: neutrophils/leukocytesa, 
eosinophils/leukocytesa, 
lymphocytes/leukocytesa, 
monocytes/leukocytesa. 
Coagulation/hemostasis 
Coagulation 
Prothrombin time, aPTT 
Clinical chemistry 
Electrolytes 
Sodium, chloride, potassium, total 
calcium 
Enzymes 
Creatine kinase 
Hormones 
FSH 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 32 of 39 
Table 11‒1: Clinical laboratory measurements 
Category 
Panel 
Variable 
Metabolic 
Glucose 
Kidney function 
BUN, creatinine 
Proteins 
Total protein, albumina 
Liver function 
ASTa, ALTa, GGT, ALP, LDH, total 
bilirubin 
Lipids 
Total cholesterola, LDL cholesterola, 
HDL cholesterol, triglycerides 
Urinalysis 
Dipstick 
pH, protein, glucose, ketone, 
urobilinogen, bilirubin, blood, specific 
gravity, nitrite, and leukocytes 
Other tests 
Urine alcohol test/drug screen 
Ethanol (measured using a urine 
alcohol test).  
Urine drug screen: 
amphetamines/methamphetamines, 
barbiturates, benzodiazepines, 
tetrahydrocannabinol, cocaine, tricyclic 
antidepressants, phencyclidine, and 
morphine/opiates 
Pregnancy 
Prior to dosing, a serum pregnancy test 
(hCG) will be performed; post dosing 
the test may be performed in urine.  
The FSH test performed in 
postmenopausal women at the 
Screening Visit. 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; aPTT=activated partial thromboplastin time; 
AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle stimulating hormone;  GGT=gamma 
glutamyl transferase; HBc-Ab=hepatitis B core antibody; HBsAg=hepatitis B surface antigen; hCG=human 
chorionic gonadotropin; HCV-Ab=hepatitis C virus antibody; HDL=high density lipoprotein; HIV=human 
immunodeficiency virus; HIV1/2-Ab=HIV1/2 antibody; HIV1-Ag=HIV1 antigen; LDH=lactate dehydrogenase; 
LDL=low density lipoprotein; RBC=red blood cell; WBC=white blood cell 
a Shift table will be presented for this variable 
For hematology, coagulation/hemostasis, clinical chemistry and urinalysis laboratory variables 
the following summaries will be presented by treatment group: 
• Observed results and change from Baseline for numeric variables at each post-Baseline time 
point. These summaries will report the number of participants with non-missing values, 
mean, SD, median, minimum and maximum. 
• Shift tables from Baseline to each post-Baseline time point. These summaries will present a 
cross-tabulation of Baseline values against post-Baseline values categorized as below normal 
range, within normal range and above normal range. Each cell will include the corresponding 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 33 of 39 
number and percentage of participants. These summaries will only be presented for selected 
variables in Table 11‒1. 
The above-mentioned laboratory variables and change from Baseline for numeric variables will 
be listed for the FAS by treatment group and time point. Any laboratory measurements that are 
BLQ or ALQ will be handled as described in Section 4.2.2. Values outside the normal ranges 
will be flagged and the listings will present reference ranges. Additionally, laboratory results 
outside reference ranges will be listed by treatment group and time point for the FAS. 
Data for the following will only be listed using the ES by treatment group and time point: 
• Serology 
• Urine alcohol test/drug screen 
• Pregnancy tests (serum and urine) 
• Follicle stimulating hormone (FSH) (only for postmenopausal women). 
11.3.1 
Potential drug-induced liver injury 
A separate listing will present participants who meet one or more of the following potential drug 
induced liver injury (PDILI) criteria at any visit: 
• Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≥3x Upper limit of 
normal (ULN) and Total bilirubin <2x ULN who no exhibit temporally associated symptoms 
of hepatitis or hypersensitivity 
• ALT or AST increase ≥3x ULN and Total bilirubin ≥2x ULN 
• ALT or AST ≥3x ULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity 
Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without 
clear alternative cause). 
The listing will display only visits for which at least one of the above criteria was fulfilled for a 
given participant and will display all results obtained at that visit for the specified parameters. 
A summary of participants who met the criteria for PDILI will be presented together with any 
additional relevant data collected, if applicable. 
11.4 
Vital signs, physical findings, and other observations related to 
safety 
11.4.1 
Vital signs 
The following vital signs measurements will be obtained: 
• Pulse rate 
• Systolic and diastolic blood pressure 
• Oral body temperature 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 34 of 39 
Descriptive statistics will be reported for the above vital sign measurements. Measured values 
and changes from Baseline will be summarized by vital sign variable and time point for each 
treatment group. These summaries will be presented for the FAS. 
By-participant listings of all vital sign measurements and change from Baseline will be presented 
by treatment group and time point for the FAS. 
11.4.2 
Electrocardiograms 
Single 12-lead ECG recordings will be taken prior blood sampling and with the study participant 
resting in the supine position for at least 3 minutes. The following variables will be reported: 
• Heart rate 
• PR interval 
• QRS duration 
• QT interval 
• QT corrected for heart rate using Fridericia’s formula (QTcF = QT/RR1/3) 
The results of all ECG variables will be reported in the by-participant listings for the FAS. The 
listing will also include the change from Baseline and percentage change from Baseline and will 
be presented by treatment group and visit/timepoint. 
Measured values, changes and percentage changes from Baseline will be summarized for the 
FAS, for each variable by treatment group and visit/timepoint.  
The following cut-points in QTcF (raw data and change from Baseline) will be summarized for 
the FAS, categorically by treatment group (number and percentage of participants) and 
visit/timepoint. The denominator for the percentages will be the number of participants with a 
non-missing measurement for the variable at the specific visit/timepoint. 
Raw QTcF data: 
• <450msec 
• ≥450msec to <480msec 
• ≥480msec to <500msec 
• ≥500msec 
Change from Baseline QTcF: 
• <30msec 
• ≥30ms to <60msec 
• ≥60msec 
Electrocardiogram findings will be listed separately. 
11.4.3 
Physical examinations 
Participants with abnormalities in the physical examination will be listed including details of the 
abnormality. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 35 of 39 
12 
OTHER ANALYSES  
A listing of comments will be provided, if applicable. This will be based on the RS. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 36 of 39 
13 
REFERENCES 
1. Phillips, A. and Haudiquet, V. (2003), ICH E9 guideline ‘Statistical principles for clinical 
trials’: a case study. Statist. Med., 22: 1-11. doi:10.1002/sim.1328 
2. Food and Drug Administration. Guidance for Industry. Bioavailability and Bioequivalence 
Studies Submitted in NDAs or INDs —General Considerations. US Dept of Health and 
Human Services, Center for Drug Evaluation and Research. Biopharmaceutics. March 2017. 
3. EMEA/CHMP/BMWP/42832/2005 Rev. 1 Guideline on similar biological medicinal 
products containing biotechnology-derived proteins as active substance: non -clinical and 
clinical issues , 18 Dec 2014. 
4. CPMP/EWP/QWP/1401/98 Rev. 1/Corr Guideline on the investigation of bioequivalence 
(EMEA), 20 January 2010. 
5. Health Canada Guidance, Conduct and Analysis of Comparative Bioavailability Studies, 8 
Jun 2018. 
6. Health Canada Guidance, Comparative Bioavailability Standards: Formulations use for 
Systemic Effects, 8 Jun 2018. 
7. EMA. Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) 
pandemic. Version 3. 28 Apr 2020. Available at: 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-
10/guidanceclinicaltrials_covid19_en.pdf  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 37 of 39 
14 
APPENDICES 
<Enter text> 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 38 of 39 
15 
AMENDMENT(S) TO THE STATISTICAL ANALYSIS PLAN 
(SAP) (IF APPLICABLE) 
<Enter text> 
15.1 
AMENDMENT 1 
Rationale for the amendment 
<Enter text> 
Modifications and changes 
Global changes 
<Enter text> 
Specific changes 
<Enter text> 
Has been changed to: 
<Enter text> 
15.2 
AMENDMENT 2 
<Enter text> 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB 
 
17 Nov 2020 
Statistical Analysis Plan 
Bimekizumab 
UP0068 
 
 
 
Confidential 
Page 39 of 39 
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE 
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution. 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


Approval Signatures
Name:
UP0068-SAP
Version:
1. 0
Document Number:
CLIN-000162152
Title:
UP0068-SAP
Approved Date:
19 Nov 2020
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Clinical
Date of Signature: 18-Nov-2020 19:28:15 GMT+0000
Approval
Verdict: Approved
Name: 
Capacity: Subject Matter Expert
Date of Signature: 19-Nov-2020 11:17:22 GMT+0000
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.